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ABSTRACT 
Differential diagnosis of familial chorea encompasses Huntington’s disease along with a group of 
conditions referred to as Huntington’s disease-like (HDL). One such HDL is an inherited prion 
disorder (IPD) caused by pathological insertions of 8 additional OPRIS in the prion protein gene 
(PRNP). Only four 8-OPRI families have been reported, one of which was Swedish. Polymorphism 
in codon 129 of the PRNP gene, alternating between methionine (M) and valine (V), is the primary 
modulator of prion diseases. The Swedish family had the longest survival of any 8-OPRI family. 
Patients carrying 129M in the mutated allele demonstrated earlier age of onset (AO), longer survival 
and earlier age of death than those with 129V. PRNP polymorphism in codon 129 together with 
gender determined as much as 50% of the variability in AO. An inverse correlation between early AO 
and length of survival was observed (Paper I). 
Ataxia with oculomotor apraxia type 4 (AOA4) is caused by mutations in the gene encoding 
polynucleotide kinase 3-prime phosphatase (PNKP) gene. A Swedish patient withAOA4 due to 
compound PNKP mutations, progressive symptoms and cerebellar atrophy was characterized (Paper 
II). Novel AOA4 features in this case were chorea during childhood, slower disease progression than 
previously described and low levels of the PNKP protein in her lymphocytes.  
Spinocerebellar ataxia type 4 (SCA4), a rare disease first described in a Scandinavian family in the 
American Midwest in 1996 has been found to be linked to chromosome 16q22.1. A second SCA4 
family was later identified in Germany. Two Swedish SCA4 families with novel symptoms such as 
dystonia and dysautonomia are described here. Symptom onset was at middle age and anticipation was 
suggested in one family.  Variable infratentorial atrophy and spinal cord atrophy was evident in all the 
tested patients. Flumazenil-PET revealed reduced binding in several brain regions including the insula, 
thalamus, hypothalamus and cerebellum.  The candidate region was sequenced but no pathogenic 
variants were found. Widespread neurodegeneration was exhibited by two cases (Paper III).  
Primary familial brain calcifications (PFBC) are heterogeneous diseases. One Swedish-Finnish family 
(F13) with such calcifications and associated migraine, hyperkinesias and psychiatric symptoms 
associated is described along with five other PFBC families. The F13 family harbors the L9R mutation 
in the platelet-derived growth factor beta polypetide (PDGFB) gene. Other PDGFB mutations were 
identified in the remaining families. A hypomorphic PDGFB 
ret/ret
 mouse model displays brain 
calcifications and an impaired blood-brain barrier (BBB).  Paper IV established mutations in PDGFB 
as the second most common cause of PFBC, after mutations in SLC20A2. Later, cognitive deficits, 
progressive hyperkinesias and calcifications in the F13 family were documented; CSF-NfL was 
elevated, but oxysterol levels were normal in all tested patients indicating that the BBB was intact 
(Paper V).  One patient harboring the R467X mutation in SLC20A2 and affected by ataxia, dementia, 
and progressive brain calcifications is described (Paper VI).  SLC20A2 encodes sodium-dependent 
phosphate transporter 2. As in SLC20A2 knockout mouse models, the level of phosphate in her CSF 
was elevated as was her CSF-NfL. In both the F13 family and the carrier of SLC20A2 mutation a 
coregistration was employed to evaluate the progression of calcification.  
GBA1 mutations and variants are risk factors for Parkinson’s disease (PD) and other types of 
parkinsonism. The GBA1 gene is mutated in connection with Gaucher disease (GD). A GD1 cohort (n 
=13) and a GD3 cohort (n=12) were examined. In the GD1 cohort two PD cases were identified but 
none in the GD3 cohort. Abnormal DAT scan was found in 1 GD3 patient and hyposmia was present 
in 44%. Six GD3 patients have lived beyond 40 years of age. Dystonia was documented as a novel 
feature in GD3. Neither group had detectable neurological progression during 3 years (Paper VII).   
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1. What are movement disorders? 
Movement disorders are classified either as hyperkinesias (excess of movements) or 
hypokinesias (a paucity of movements) unrelated to spasticity or weakness (1). Parkinsonian 
syndromes are by far the most common cause of hypokinesias.  Other terms for hypokinesias 
include akinesia (loss of movement), bradykinesia (slowness of movement) and hypokinesia 
(decreased amplitude of movements) while alternative names for hyperkinesias are 
dyskinesias and abnormal involuntary movements. The most common hyperkinesias include 
ataxia, chorea, dystonia, myoclonus, tics and tremor (1) (Table 1). The term ataxia, derived 
from the Greek word for chaos, (also known as asynergia and dyssynergia) describes impaired 
balance and coordination most often as the result of cerebellar impairment.  Chorea, from the 
Greek word for dance, consists of random involuntary, rapid, irregular and non-sustained 
movements. Dystonia are sustained and repetitive movements involving agonist and 
antagonist muscles and leading to abnormal postures. Myoclonic jerks are brief, shock-like 
involuntary movements caused by muscular contractions (positive myoclonus) or inhibitions 
(negative myoclonus). Tics are abnormal movements or sounds usually preceded by a sensory 
urge. Tremor is an oscillatory and rhythmic movement caused by alternating or simultaneous 
contractions of agonist and antagonist muscles, the location, amplitude and rate of which 
varies (1) 
2. The choreic patient 
Assessing the etiology of chorea involves its presentation (insidious or subacute), age of onset 
(AO), family history and history of exposures, as well as a thorough physical exam. Although 
family history may provide some clues its absence does not exclude a genetic disease. 
Associated features and diagnostic signs are searched for employing a variety of ancillary 
tests including a wide range of laboratory analyses, blood smears, neuroimaging and/or 
neurophysiological exams (2, 3).   
Huntingtonism can be acquired or familial, and chorea is often the side-effect of a drug or 
caused by structural lesions in the basal ganglia. For instance, patients with Parkinson’s 
disease (PD) develop dyskinesias after long-term treatment with levodopa (L-DOPA) and 
tardive dyskinesia is a complication observed in patients treated with neuroleptics. Stroke or 
other lesions in the striatum, brain calcifications (either primary or secondary), complications 
associated with metabolic disorders (e.g., non-ketotic hyperglycemia) and 
autoimmune/parainfectious diseases are other causes of chorea. Sydenham’s chorea is 
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common in children, while paraneoplastic chorea is in general rare. Etiological diagnosis is 
crucial for the proper clinical management, prognosis and, for familial cases, genetic 
counselling. The etiology of acquired chorea and its work-up have been reviewed anywhere 
else (2–4).  
Table 1. Summary of Movement Disorders 
Hyperkinesias Hypokinesias 
Akathisia 
Ataxia 
Athetosis 
Ballism 
Chorea 
Dystonia 
Hemifacial spasm 
Hyperekplexia 
Hypnogenic dyskinesias 
Jumping stumps 
Moving toes and fingers 
Myoclonus 
Myokymia 
Myorhytmia 
Paroxysmal dyskinesias 
Periodic movements in sleep 
REM sleep behavior disorder 
Restless legs 
Stereotypy 
Tics  
Tremor 
Apraxia 
Blocking tics 
Cataplexy 
Catatonia 
Freezing of gait/ Hesitant gait 
Hypothyroid slowness 
Rigidity 
Stiff muscles 
 
Adapted from Fahn S, Jankovic J and Hallett M. Principles and Practice of Movement 
Disorders, 2
nd
 edition, Elsevier Health Sciences; 2011.  
 
3. Huntington’s disease (HD) 
The nine familial neurodegenerative disorders referred to collectively as polyglutamine 
diseases are caused by expansions of the cytosine-adenine-guanine (CAG) sequence, which 
encodes glutaimine (Q), in exons of various genes (5) (Table 2). All but one of these disorders 
is inherited in an autosomal dominant (AD) manner. The polyQ disorders, of which the most 
common is Huntington’s disease, share traits such as adult-onset, anticipation and certain 
neuropathological abnormalities. The most common disorder in the polyQ group is 
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Huntington’s disease (HD). SCA12 is another disease associated with CAG expansions, but 
the expansion is located in the 5’UTR region of the PPP2R2B gene (6).    
Table 2: Summary of polyQ disorders and associated genes 
Disease Pattern of 
inheritance 
Gene  MIM number 
Huntington’s disease (HD) 
SCA 1 
SCA2 
SCA3 
SCA6 
SCA7 
SCA17 
DRPLA 
SBMA or Kennedy’s 
disease 
AD 
AD 
AD 
AD 
AD 
AD 
AD 
AD 
XL 
HTT 
ATXN1 
ATXN2 
ATXN3 
ATXN6 
ATXN7 
TBP 
ATN1 
AR 
613004 
601556 
601517 
607047 
601011 
607640 
600075 
607462 
313700 
 
AD: autosomal dominant; DRPLA: dentatorubropallidoluysian atrophy; SBMA: spinal and 
bulbar muscular atrophy; SCA: spinocerebellar ataxia; XL: X-linked. 
 
The original description provided by young George Huntington in 1872 was succinct, but still 
regarded as complete (7).  Usually presenting between 35 and 44 years of age, HD is 
characterized by progressive symptoms that include involuntary movements, 
psychiatric/behavioral symptoms and cognitive decline, often leading to dementia (8). 
Although the characteristic feature chorea was considered to be the diagnostic gold standard, 
longitudinal observations have revealed that insidious non-motor features are present early in 
the course of disease (8–10). Other associated motor features include impaired voluntary 
control, dystonia, hypokinesia, oculomotor abnormalities, dysarthria and dysphagia (11,12) 
Affective symptoms (depression and anxiety) and lack of insight are very common, suicidal 
ideation and suicide risk are elevated. Varying degrees of irritability, impulsiveness, psychotic 
symptoms, apathy and obsessive behavior occur and can become problematic (8). The 
cognitive decline is characterized by the early occurrence of executive dysfunction and 
psychomotor slow-down. Deficits in memory, emotional recognition and attention occur as 
well and all these symptoms progress into dementia . Other common characteristics include 
weight loss, sleep disturbances and dysautonomia (8). The rare juvenile form of HD (JHD) 
also called Westphal variant, is defined by  onset before age 20 and representing only 5% of 
all HD cases, is more severe than the adult form and is associated with other symptoms such 
as epilepsy, myoclonus and parkinsonian features at earlier stages (8).  Life expectancy after 
  14 
onset is usually 15-18 years (12). Treatment remains symptomatic, but major advances in 
recent years have paved the way for the ongoing clinical involving gene silencing that was 
started in 2015 (13,14).  
The geographical distribution of HD varies and its frequency thought to be increasing (15). 
The highest prevalence of HD around the Maracaibo Lake in Venezuela probably reflects a 
founder effect (16). Although more common than originally thought, especially among 
Caucasians, this disease is rare in Asian and African populations (15). The United Kingdom is 
estimated to have about 12 cases per 100 000 inhabitants (17).  
A radiological hallmark of HD is the presence of striatal atrophy particularly in the caudate 
nucleus, as confirmed in the TRACK HD study which found that such atrophy precedes the 
disease presentation by a decade (18). Such caudate atrophy is not specific for HD, being 
found in HDL2 and neuroacanthocythosis syndromes as well. The TRACK HD longitudinal 
assessment of HD also revealed progressive atrophy of the white matter in presymptomatic 
subjects and in those with early stage disease (18).   
 3.1 The genetics of HD  
The discovery of a marker in the short arm of chromosome 4 in 1983 made genetic testing 
possible for the first time (19). Ten years later, the underlying pathological CAG expansion in 
exon 1 of the HTT gene was identified (20). The size of this expansion shows an inverse 
correlation to AO (21). Healthy subjects usually have 7-12 CAG repeats and can have as 
many as 26. The range of intermediate alleles is 27-35 CAG repeats. Penetrance is incomplete 
with 35- 39 CAG repeats and complete with a larger number. Larger CAG repeat expansions 
are associated with greater instability and higher risk for additional expansion in subsequent 
generations. The size of the CAG expansion determines 44% of the variability in the AO 
among mutation carriers, with the vast majority of HD patients exhibiting 40-50 CAG repeats 
which represent (20). A genome-wide association (GWAS) analysis revealed two associated 
loci with modification of AO (22). 
4. Huntington’s disease-like (HDL) 
HD is by far the most common cause of familial chorea and the most common familial 
neurodegenerative disease (23), among patients referred for suspected Huntington’s disease, 
1% lack the pathological nucleotide expansion in HTT (24-26) and these conditions are 
referred to as Huntington’s disease-like (HDL) or HD phenocopies (Table 3). Among 285 
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patients of this kind, only 2.8% were properly diagnosed (23) and the results of several other 
screenings performed since 2002 have been variable (27–38). Algorithms for the diagnosis of 
HDL syndromes have been proposed over the years and adapted to recent discoveries and 
technologies (3, 35). When I began my thesis work in 2011 the most common HDL in 
Western populations was by far spinocerebellar ataxia type 17 (SCA17). In the largest HDL 
screening to date including 1712 German and Austrian patients, 9 such cases were detected 
(27). Previously, an inherited prion disease (IPD) with 8-OPRI was reported in Sweden and 
later termed Huntington’s disease-like (HDL1) (39, 40). Only one of the HDL screenings 
identified another case of IPD (23).  
Table 3: Summary of HD phenocopies, c9orf72 mutations and SCA17 are the most 
common HDL syndromes in Caucasian populations. 
Disease Pattern of 
inheritance  
Gene MIM number 
c9orf72 mutations 
HDL1  
HDL2 
SCA1 
SCA2 
SCA3/MJD 
SCA17 
DRPLA 
BHC 
Neuroferritinopathy 
ADCY5-related dyskinesia 
McLeod syndrome 
Chorea-acanthocytosis 
AD 
AD 
AD 
AD 
AD 
AD 
AD 
AD 
AD 
AD 
AD 
XL 
AR 
c9orf72 
PRNP 
JHP3 
ATXN1 
ATXN2 
ATXN3 
TBP 
ATN1 
NKK2 
FTL 
ADCY5 
XK 
VPS13 
614260 
176640 
605268 
601556 
601517 
607047 
600075 
607462 
600635 
134790 
600293 
314850 
605978 
AD: autosomal dominant, AR: autosomal recessive, BHC: benign hereditary chorea, DRPLA: 
dentatorubropallidoluysian atrophy, HDL: Huntington’s disease like, SCA: spinocerebellar 
ataxia, XL: X-linked.  
 
Other important AD HDLs include Huntington’s disease-like 2 (HDL2) and c9orf72 
mutations. The former afflicts predominantly patients of African ancestry (41–43) whereas a 
screening of 514 English patients with HDL identified pathological nucleotide expansions in 
c9orf72 in 10 patients (1.95%) making this the second most common cause of familial chorea 
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after HD (35). Two much smaller screenings appear to confirm that c9orf72 mutations are a 
common cause of HDL (38, 44). The clinical presentations of HD and other polyQ disorders, 
in particular spinocerebellar ataxia type3/Machado Joseph disease (SCA3/MJD) and 
dentatorubropallidoluysian atrophy (DRPLA) overlap to some degree. Sometimes chorea is 
associated with SCA1 and SCA2 (3) although two HDL screenings found no SCA1, SCA2, 
SCA3 or DRPLA cases (23,34). 
4.1 c9orf72 mutations 
Over 60 hexanucleotide GGGGCC expansions in the first intron of the c9orf72 gene are 
associated with a spectrum of AD frontotemporal dementia and/or amyotrophic lateral 
sclerosis (FTD/ALS) (45). Such mutations have reduced penetrance (46), and constitute the 
most common cause of familial ALS (25%) as well as accounting for 12% of familial FTD. 
The mean AO among the 10 HDL patients associated with c9orf72 mutations was 42.7 years 
(range 8-60 years). Their clinical presentation involved predominant movement disorders, 
cognitive decline and early psychiatric symptoms. Rigidity and bradykinesia were more 
common than chorea, with 40% displaying upper motor neuron signs. Six of these 
demonstrated impaired memory and executive functions, while general brain atrophy was 
evident in 4 of 8 (35). Atypical parkinsonism has also been attributed to c9orf72 mutations 
(47).  
4.2 Spinocerebellar ataxia type 17 (SCA17)  
Although SCA17, caused by a pathological CAG expansion is in the gene encoding the 
TATA-binding protein, (TBP) was initially described in Japan, this disease is panethnic (48–
50). The phenotype varies widely, including, in addition to ataxia and chorea, other motor 
abnormalities such as parkinsonism in combination with cognitive decline and/or seizures (51, 
52).  
4.3 Huntington disease-like 1   
Most inherited prion diseases (IPD) cases are caused by point mutations or mutations in the 
PRNP gene that cause premature termination of transcription. Fewer mutations in this context 
involve insertions of extra octapetide repeats (OPRI) with insertion of 4-12 such repeats 
leading to highly variable phenotypes (53–55). F. Xiang and colleagues reported a Swedish 
family affected by a HD phenocopy later labelled as Huntington disease-like 1 (HDL1) (39). 
These patients displayed rapidly progressing dementia and severe psychiatric symptoms, as 
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well as a variable degree of rigidity, ataxia and chorea. HDL1 is caused by insertion of extra 
8-OPRI into the PRNP gene (40). Insertions of 6-OPRIs carried by a large English family 
have been reported to result in an HDL phenotype (23). 
4.4 Other forms of HDL 
Other forms of HDL include Huntington disease-like 2 (HDL2). The mutation underlying 
HDL2, originally described in an African American family, involves CTG/CAG repeat 
expansions in the junctophilin gene (JPH3) (41, 56). To date, only two patients of non-
African ancestry have been diagnosed with this disease (23, 57). As in the HD cases, the 
length of the expansion is inversely correlated with the AO. HDL2 accounts for 1% of HDL 
cases in North America (30). The similarities between its clinical and radiological features 
and those of HD make it difficult to distinguish between these two (41).  
Benign hereditary chorea (BHC), ADCY5-related dyskinesia, neuroferritinopathy and 
paroxysmal dyskinesias are other AD HDL. Symptom onset of BHC usually occurs during 
childhood and spontaneous amelioration over time is common. BHC is also associated with a 
broad spectrum of neurological symptoms including ataxia and dystonia, as well as non-
neurological features such as hypothyroidism and pulmonary symptoms (58). Mutations in the 
ADCY5 gene are associated with complex phenotypes that include in addition to 
hyperkinesias, delay of motor milestones and exacerbations of other motor features. Some 
patients display non-progressive disease, as well as hypotonia and a varying degree of 
intellectual disability (59–61). Paroxysmal dyskinesias are associated with mutations in the 
GLUT1 and PRRT2 genes.  Primary familial brain calcifications (PFBC), a group of AD 
disorders with variable presentation, are discussed in detail below in section 8.1. 
Neuroferritinopathy, aceruloplasminemia and other conditions included in the category of 
neurodegeneration with brain iron accumulation (NBIA) display distinctive radiological 
features (62, 63). 
Autosomal recessive (AR) HDL phenotypes include Wilson disease. Chorea can be one 
feature of mixed AR movement disorders, such as the ataxia syndromes associated with 
oculomotor apraxia (OMA). A new disorder of this type, ataxia with oculomotor apraxia type 
4 (AOA4), has been associated with dystonia (64), see also section 6.1 below. Certain experts 
group Friedreich ataxia together with the HDL group (3, 23). Recently, a homozygous 
mutation in GPR88 was described in siblings with a complex syndrome with chorea (65). The 
most important neuroacanthocytosis syndromes are AR chorea-acanthocytosis and the X-
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linked (XL) McLeod syndrome (MLS). Other XL conditions presenting with hyperkinesias 
include Lesch-Nyhan syndrome, Lubag disease and Rett syndrome. Chorea occurs in 
connection with mitochondrial disorders like mitochondrial encephalomyopathy, lactic 
acidosis, and stroke-like episodes (MELAS) and Leigh syndrome among others (3). In 
addition to GLUT1 deficiency, the metabolic conditions associated with chorea include 
phenylketonuria, glutaric acidemia type I, methylglutaconic aciduria type III and certain 
aminoacidopathies (3). Additional novel and usually sporadic syndromes are associated with 
mutations in PDE10A, RNF216, GNAO1, FOXG1 and SCN8A (66). 
5. Prion diseases 
The rare and fatal prion diseases affect mammals only. Establishment of prions 
(proteinaceous infectious particle) initially as the cause of scrapie and later of severe 
neurodegenerative disease in humans, has had far-reaching repercussions (67), especially in 
the light of reports suggesting that α-synuclein, the protein that aggregates in Parkinson’s 
disease, spreads and induces protein aggregation in the brain via a prion-like mechanism (68).  
A similar mechanism has been proposed and debated for huntingtin, tau and superoxide 
dismutase among other proteins that undergo abnormal aggregation (69).  
 
The “prion only hypothesis of disease” states that an abnormal prion protein (PrPSc) replicates 
itself by inducing conformational changes in copies of the native prion protein (PrP
C
), 
changes that lead to spongiphorm encephalopathy, the pathological hallmark of prion 
diseases. Accordingly, prion diseases are also known as transmissible spongiphorm 
encephalopathies (TSEs). The outbreak of bovine spongiphorm encephalopathy (BSE), 
referred to as ‘Mad Cow Disease’ by the media, in the United Kingdom in the 1990’s had a 
major impact on the national economy and public health. A novel prion disease, called variant 
Creutzfeldt-Jakob disease (vCJD) and affecting young individuals emerged in the United 
Kingdom and was shown to be caused by the BSE prion strain (70).  
 
Molecular classification of prion diseases is based on a combination of prion protein strain 
(PrP) and genotype (71). Assessment of neuropathology and transmission are also central 
aspects of the characterization of prion diseases. Although transmission can be investigated by 
inoculating brain homogenates into transgenic mice expressing the human PRNP gene, it 
should be noted that not all human prion strains are transmissible (72). Human prion diseases 
are also classified as sporadic, acquired, or familial.   
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5.1 Sporadic prion diseases  
This subgroup of human prion diseases is represented by sporadic Creutzfeldt-Jakob disease 
(sCJD), which with its prevalence of 1-2 cases per million, accounts for 85% of all cases of 
prion disease. The main feature of sCJD, which usually affects elderly people, is a rapidly 
progressing dementia in association with extrapyramidal symptoms, ataxia, behavioral and/or 
visual disturbances (73).  
 
5.2 Acquired prion diseases  
In addition to vCJD which is mentioned above, this subgroup includes kuru, as well as 
iatrogenic CJD (iCJD). Kuru afflicted the Fore people of eastern New Guinea and was caused 
by the ritual ingestion of the organs of dead relatives (74). iCJD is acquired through 
contaminated surgical instruments, hormone extracts from the pituitary glands of cadavers 
and through meningeal and corneal transplantations.  
 
5.3 Familial prion diseases 
10-15% of all prion diseases are caused by mutations in the prion gene (PRNP) located on the 
short arm of chromosome 20 (75). These mutations exhibit an AD pattern of inheritance and 
are associated with a wide range of phenotypes, the most common being familial CJD (fCJD), 
followed by Gertsmann-Sträussler-Scheinker syndrome (GSS) and familial fatal insomnia 
(FFI). The symptoms of GSS include ataxia, cognitive decline and extrapyramidal disorders. 
The FFI phenotype involves dementia, insomnia and dysautonomia. The clinical 
manifestations of a new familial prion disease described by S. Mead et al in 2013 and 
associated with cerebral amyloid angiopathy include chronic diarrhea, autonomic failure, 
polyneuropathy, cognitive decline and epilepsy (76). P102L, A117V, D178N, and E200K 
account for more than 50% of all PRNP mutations (77). 
 
5.3.1 Polymorphism in codon 129 of the PRNP gene 
Polymorphism in codon 129 of the PRNP gene, which encodes either methionine (M) or 
valine (V), demonstrates a remarkably strong association with prion diseases. Among Western 
populations 38% carry MM, 51% MV and 11% VV (78). This polymorphism influences not 
only susceptibility to prion disease, but also the incubation period prior to the development of 
acquired prion disease and the clinical phenotype associated with all forms of prion disease 
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(78,79). For instance, as many as 80-90% of patients with sCJD are homozygous at codon 
129. In addition, all cases of vCJD definitively diagnosed so far except one have had the MM 
genotype (80). Early onset in kuru among homozygotes is probably due to a predominantly 
shorter incubation time, while onset at a later age was more common among heterozygotes 
(81). This also appears to be the case for iCJD and has been proposed for vCJD as well 
(80,82). In general, homozygoty is associated with earlier AO of familial prion diseases (54). 
Another modulation occurs with the mutation D178N in PRNP, when the mutated allele is 
129M the associated phenotype is FFI and fCJD when it is 129V (83).  
 
5.3.2 Extra octapeptide repeats insertions (OPRI) 
Most cases of IPD are caused by conventional mutations, but additional octapeptide repeats 
insertions (OPRI) into the PRNP gene, also known as base pair insertions (BPIs), account for 
a minority of mutations. Insertions of additional 2-12 OPRI in the N-terminal region of PRNP 
are pathogenic (53, 55, 84, 85) whereas loss of a single OPRI is considered to be a 
polymorphism (75). The N-terminal region normally contains one nonapeptide (R1) followed 
by four octapeptide units (R2-R4) (54).  
Only four families afflicted by IPD with 8-OPRIs and with varying phenotypes have been 
described, two unrelated French families (Che and M-E), one wDutch (family A) and the 
fourth Swedish. Four of the seven patients in the Swedish family displayed chorea which was 
initially attributed to HD (39, 40, 86–88)  After HD had been ruled out, this presentation was 
designated HDL1 (89). At the time F. Xiang and colleagues described this family, three of its 
affected members were still alive (39). The HDL1 phenotype is characterized by rapidly 
progressing cortical dementia, a variety of movement disorders, and manifest 
psychiatric/behavioral symptoms. It is noteworthy that some patients belonging to the French 
M-E family exhibited learning disabilities early in life (88) and antisocial behavior was 
evident in a large English family with 6-OPRI (90). All of the patients in the Swedish 8-OPRI 
family are now deceased.   
When this thesis was being planned, the effect of the polymorphism in codon 129 of PRNP 
gene on the disease phenotype of IPD with 8-OPRI remained to be characterized. The prion 
strain underlying this mutation is still unknown. Despite a thorough initial description, the 
prion-oriented neuropathology of the Swedish 8-OPRI family has not been examined. 
Varying degrees of cell loss, spongiosis, and astrocytosis in different areas of the brain have 
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been described in IPD with 8-OPRI (39, 86, 87). In addition PrP plaques were detected in the 
cerebellum and, to a lesser degree, in the striatum, temporal and parahippocampal cortex (87, 
88, 91, 92). Using brain homogenate from one patient of the Che family, transmission to a 
monkey was achieved (86) although not with a similar preparation from the M-E family (88). 
Transmission studies involving transgenic mice remain to be performed.  
6. Ataxia with oculomotor apraxia (AOA) 
Autosomal recessive cerebellar ataxias (ARCA) with oculomotor apraxia are complex and 
incurable syndromes commonly associated with mutations in genes encoding proteins 
involved in DNA repair which usually debut early in life (93). The first such disease to be 
described was ataxia telangiectasia (A-T), which is caused by mutations in the ATM gene 
(94). The A-T phenotype involves of progressive and disabling axial ataxia, peripheral 
neuropathy, choreoathetosis and variable intellectual disability. Later AO, dystonia and 
slower progression characterize variant AT in which some enzyme activity remains (94–97). 
In addition to the neurological features, a wide range of features such as the presence of 
telangiectasias, sensitivity to ionizing radiation, immunodeficiency with recurrent infections, 
and pulmonary symptoms are associated with A-T. There is also a remarkable increased in the 
risk for malignancy, in particular leukemias and lymphomas (94). All these features explain 
the reduced life expectancy in A-T. Increased levels of alpha-fetoprotein (AFP) are found in 
the vast majority of A-T patients (94).  
Ataxias with oculocephalic dissociation also include ataxia-telangiectasia-like disorder 1 
(ATLD1), ataxia-telangiectasia-like disorder 2 (ATLD2), spinocerebellar ataxia with axonal 
neuropathy (SCAN1), ataxia with oculomotor apraxia type 1 (AOA1), ataxia with oculomotor 
apraxia type 2 (AOA2), ataxia with oculomotor apraxia type 3 (AOA3) and the recently 
described ataxia with oculomotor apraxia type 4 (AOA4) (64, 93, 98–101). Elevated levels of 
AFP but normal serum levels of albumin and cholesterol are the biochemical hallmarks of AT 
and AOA2. Hypoalbuminemia and hypercholesterolemia with normal AFP are found in 
patients with AOA1 and AOA3 (101). The main features of these various conditions are 
summarized in Table 4. Ataxia can occur in association with familial RAD50 deficiency and 
RNF168 deficiency syndrome, but this is extremely rare (102,103). 
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Table 4: Differential diagnosis in ataxia-telangiectasia and related disorders 
 
All genes in this table except PIK3R5 code for proteins involved in DNA repair. AOA1-4: ataxia with oculomotor apraxia1-4, A-T: ataxia telangiectasia, ATLD1/2: ataxia-
telangiectasia-like disorder ½, EPS: extrapyramidal symptoms, SCAN1: ataxia with oculomotor apraxia type 1, Y: yes, N: no, N.A.: not assessed.  
References: 1. Le Ber I, Dürr A, Brice A. Autosomal recessive cerebellar ataxias with oculomotor apraxia. Handb Clin Neurol. 2012;103:333–41. 2. Baple EL, Chambers H, Cross 
HE, et al. Hypomorphic PCNA mutation underlies a human DNA repair disorder. J Clin Invest. 2014 Jul;124(7):3137–46. 3. Coutinho P, Barbot C. Ataxia with Oculomotor Apraxia 
Type 1. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJ, et al., editors. GeneReviews(®) [Internet]. Seattle (WA): University of Washington, Seattle; 
1993 [cited 2017 Feb 1]. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1456/ 4. Bras J, Alonso I, Barbot C, et al. Mutations in PNKP cause recessive ataxia with oculomotor 
apraxia type 4. Am J Hum Genet. 2015 Mar 5;96(3):474–9. 5. Paucar M, Malmgren H, Taylor M, et al. Expanding the ataxia with oculomotor apraxia type 4 phenotype. Neurol 
Genet. 2016 Feb;2(1):e49.  
 Disorder  AT ATLD1 ATLD2 AOA1 AOA2 AOA3 AOA4 SCAN1 
Gene ATM MRE11A PCNA APTX1 SETX PIK3R5 PNKP TDP1 
Mean age of onset  (years) < 5 2 Childhood 4.3  13 15.6 4.3 13.7 
Ataxia Y Y Y Y Y Y Y Y 
OMA Y Y N Y Y Y Y N 
Intelectual disability Y N Y Y N N.A. Y N 
Dystonia Y Y N Y Y N Y N 
Chorea Y Y N Y Y  N Y N 
Peripheral  neuropathy Y Y N.A. Y Y Y Y Y 
Other features Variant AT 
can lack 
ataxia 
Myoclonus Hearing loss 
 Short stature 
Photophobia 
 
Severe course EPS are milder 
and less common 
than in AOA1 
and AOA4 
Only one family Severe course 
 
Only one family 
Pes cavus 
Seizures 
Telangiectasias Y N Y N N N N N 
Immunodeficiency Y N N N N N N N 
Increased malignancy risk Y N Y N N N N N 
Obesity N N N N N N Y N 
Cerebellar atrophy Y Y Y Y Y Y Y Y 
AFP Elevated N N N Elevated Elevated Elevated N 
Albumin Normal Normal N.A. Low Normal Normal Low levels Low levels 
Cholesterol Normal Normal N.A. Elevated Normal Normal Elevated Elevated 
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6.1 Ataxia with oculomotor apraxia type 4 (AOA4) 
In 2015 a novel syndrome resembling AOA1 and AOA2 was described in 11 patients from 8 
Portuguese families. This syndrome is associated with biallelic mutations in the PNKP 
(polynucleotide kinase 3’-phosphatase) gene and was designated ataxia with oculomotor 
apraxia type 4 (AOA4) (64). The mean AO for this progressive syndrome is 4.3 years and it 
involves ataxia, prominent peripheral neuropathy, dystonia, abnormal eye movements and 
varying degrees of cognitive impairment as well as obesity. Neuroimaging of AOA4 patients 
demonstrates cerebellar atrophy in all cases and brain stem atrophy in a few. Elevated levels 
of AFP (1.5-4-fold) were present in some, while most demonstrated hypoalbuminemia and 
hypercholesterolemia. Bras and colleagues have suggested that AOA4 is the most common 
form of AOA in Portugal (64).  
 
Initially, PNKP mutations were discovered to be associated with the severe, but non-
progressive syndrome referred to as microcephaly, early-onset, intractable seizures and 
developmental delay (MCSZ) (104). Concomitant MCSZ and hearing loss were also reported 
in a child harboring mutations in both PNKP and PCDH15 (105). Another MCSZ patient was 
also affected by short stature and dysmorphism (106). Cerebellar atrophy is also evident in the 
majority of patients with MCSZ, but in contrast to those with AOA4 can also display brain 
atrophy, a simplified gyral pattern, thinning of the corpus callosum, enlargement of the 
ventricles and reduction of withe matter (104). The homozygous PNKP variant c.58G>A  has 
been reported to be associated with epileptic encephalopathy, although this variant is probably 
benign (64,107). Patients with MCSZ exhibit an approximately ~10-fold reduction in the 
levels of PNKP protein in their lymphocytes as well as impaired repair of chromosomal DNA 
strandbreaks. Moreover, at least three such mutations reduce the stability of the PNKP protein 
and obliterate kinase activity in vitro (108).  
 
7. Spinocerebellar ataxias (SCA) 
Spinocerebellar ataxias (SCA) are highly heterogeneous autosomal dominant (AD) diseases 
numbered in order of disease discovery (SCA1-SCA43). Pathological CAG expansions in 
exons of different genes (polyQ SCA) represent the majority (~60%) of all SCA cases. One of 
these polyQ SCA, spinocerebellar ataxia type 3/Machado Joseph Disease (SCA3/MJD), is the 
most common SCA subtype globally. Until recently, SCA7 was considered the most common 
subtype in Sweden (109) however unpublished data no longer support this notion (Prof. M. 
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Nordenskjöld).  The remaining SCA subtypes are rare and caused by conventional mutations, 
variations in copy number and non-coding nucleotide expansions. The prevalence of SCA 
varies in different regions, with some SCAs occurring in very specific populations, e.g. 
SCA10 described among native populations in the Americas (110–112). Disease onset in 
SCAs with conventional mutations is usually during childhood and disease progression is 
slow. In addition, this type of SCAs is usually associated with cerebellar atrophy. Intellectual 
disability occurs in some specific types of SCA, e.g. SCA13, SCA19 and SCA27 among 
others. Poly-Q SCA are, in general, more severe diseases and associated with adult-onset, fast 
progression and atrophy in both the brainstem and cerebellum (110,113) 
7.1 Spinocerebellar ataxia type 4 (SCA4) 
SCA4, one of the rarest SCA subtypes, was first described in a Scandinavian kindred in the 
American Midwest and found to be linked to 16q22.1 flanked by the markers D16S514 and 
D16S512 (114). Adult-onset, slowly progressing ataxia and axonal sensory neuropathy are the 
hallmarks of this phenotype. This first report claimed that SCA4 was identical to Biemond’s 
ataxia described in a Dutch family, family S, in the 1950’s (114,115). Seven years later, 
Hellenbroich and colleagues described a second SCA4 family in Germany, in which the 
afflicted had cerebellar atrophy, and also narrowed the candidate region from 6 to a 3.69 cM 
interval (116).  Anticipation was suggested in both the US and German SCA4 families, 
however a search for pathological trinucleotide expansions on selective genes in the candidate 
region yielded negative results (116). While Biemond’s ataxia has been described as 
“posterior column damage”, only one neuropathological assessment of SCA4 has been 
published. Unfortunately, this assessment was limited to cerebellum and brainstem and for 
unclear reasons did not include other regions of the nervous system (117). These investigators 
found severe loss of Purkinje cells (PC) as well as demyelinization of cerebellar and 
brainstem fiber tracts, and marked neuronal loss in several brainstem nuclei (cranial nerve 
nuclei, substantia nigra and the inferior olive nucleus) (117). 
Linkage to chromosome 16q22.1 in certain Japanese families suggested the possibility of an 
allelic disorder similar to the Western SCA4.  However, the phenotype of this putative 
Japanese SCA4 was different, including hearing loss in addition to ataxia. Anticipation was 
also present but peripheral neuropathy was absent (118–120). A variant in the puratrofin-1 
(PLEKHG4) gene was proposed to be associated with this phenotype (119,121), but this 
statement was retracted when pathological pentanucleotide expansions in the gene brain-
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expressed associated with NEDD4 (BEAN1) gene were identified in these Japanese families 
and shown to be absent in the Western families with SCA4 (122,123). The Japanese SCA type 
with linkage to chromosome 16q22.1 was subsequently reclassified as SCA31 and is one of 
the most common type of SCA in Japan (124). On the other hand, cases of SCA4 are still very 
rare and the underlying mutation remains to be elucidated.  
8. Brain calcifications 
The etiology of brain calcifications is extremely broad and usually involves both acquired and 
idiopathic conditions. The most common acquired causes are mainly endocrine abnormalities  
(hypo/hyperparathyroidism, pseudohypoparathyroidism), as well as a wide range of infectious 
agents (toxoplasma, HIV and CMV, among others), trauma, autoimmune diseases, and 
exposure to certain metals (125,126).  In addition, brain calcifications are incidental findings 
on neuroimaging, particularly on the elderly, ranging from 1-20% (127,128). 
The eponym “Fahr’s disease” is taken as synonymous with idiopathic brain calcifications, but 
the wide use of this term has been questioned for several reasons. First, the clinical 
presentation with rapidly progressing tetanus and neuropathological findings described by 
Fahr are indicative of hyperparathyroidism rather than a primary or idiopathic form of brain 
calcifications. Delacour is credited with being the first to provide an accurate description of a 
probable case of primary brain calcifications in 1850 (129). Another shortcoming of the 
eponym Fahr’s disease is that it provides no information concerning the underlying etiology. 
Over the years, many other terms have been used to denote brain calcifications, as 
summarized by Manyam and colleagues (130). 
8.1 Primary familial brain calcifications (PFBC) 
Primary familial brain calcifications (PFBC) are a group of rare AD neurodegenerative 
disorders with symptom onset usually at an adult age. The clinical presentation varies 
extensively and most commonly includes a combination of movement disorders, psychiatric 
symptoms, cognitive decline and headaches/migraine; seizures are unusual. The most 
common movement disorders are hyperkinesias and Parkinsonism, whereas ataxia is 
uncommon (131–133). The symmetric calcifications affect the basal ganglia, thalamus, 
cerebellum, cortex and white matter with the brainstem being less commonly affected.  
Even though pseudohypoparathyrodism also exhibits an AD pattern of inheritance, its 
pleiotropic clinical features are strikingly different from those of PFBC and include childhood 
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onset, short stature, disabling skeletal abnormalities (due to fibrous dysplasia and fractures) 
and seizures (134). Brain calcifications also occur in connection with early-onset and severe 
AR diseases (e.g.  Aicardi–Goutières syndrome, Cockayne syndrome among others) or XL 
diseases (e.g. a rare form of familial hypoparathyroidism); these conditions have been 
reviewed anywhere else (126). Certain mitochondrial disorders, such as mitochondrial 
encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), and myoclonus with 
epilepsy and ragged red fibers in muscle (MERRF) are also associated with brain 
calcifications (135,136).  
The best way to visualize and assess brain calcifications is by computer tomography (CT) 
scans, since calcified areas demonstrate varying degrees of intensity on MRI exams 
(137,138). The degree of calcification is quantified as the Total Calcification Score (TCS) 
(131), based on visual rating of 10 different brain structures, each of which is assigned a score 
ranging from 0-5. In cases of PFBC MRI is performed to evaluate potential white matter 
abnormalities (WMA) and the integrity of infratentorial regions.  
In the only article on genetics of familial brain calcifications that had been published at that 
time, Geschwind and colleagues proposed linkage to chromosome 14q in a family with PFBC 
(139). In 2001 mutations in the SLC20A gene encoding sodium-dependent phosphate 
transporter 2 (PiT-2) were discovered to cause PFBC (140) followed by the discovery of 
mutations in the PDGFRB gene which encodes the platelet-derived growth factor receptor-β 
(141).  
Despite recent advances concerning the etiology of PFBC, information on the natural history 
of these conditions is still very limited. Also missing are tools that can help predict the 
probability of PFBC when assessing brain calcifications on incidental CT scans as well as 
biomarkers.  
9. GBA-associated parkinsonism 
Idiopathic Parkinson’s disease (iPD), the second most common neurodegenerative disorder, is 
characterized by bradykinesia, tremor, rigidity, postural instability and a broad spectrum of 
non-motor features such as enhanced risk for cognitive decline/dementia, psychiatric 
manifestations, REM sleep behavior disorder (RBD), dysautonomia, obstipation, pain and 
hyposmia, among others (142). The neuropathological hallmarks of PD are loss of 
dopaminergic neurons in the substantia nigra and deposition of α-synuclein in neurons; α-
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synuclein and ubiquitin are major components of Lewy bodies (LB) and Lewy neurites (LN). 
Other types of synucleinopathies include dementia with Lewy bodies (DLB) and multiple 
system atrophy (MSA). Despite overlapping features, the clinical and neuropathological 
features of PD differ from those of the other synucleinopathies in important respects (143). 
While PD is chronic, MSA and DLB are examples of atypical parkinsonism which associated 
with dire prognosis. Other forms of atypical parkinsonism include the tauopathies progressive 
supranuclear palsy (PSP) and corticobasal degeneration (CBD).  
For a long time PD was considered mainly a sporadic disorder, but the discovery that 
mutations in the SCNA gene, which encodes α-synuclein, cause AD parkinsonism exerted a 
major impact on research in this field (144). Subsequently, other rare forms of highly 
penetrant familial PD have also been described (Table 5), although these mutations explain 
only 3-5% of all the sporadic cases of PD (145). Moreover, a vast body of evidence has 
established that variants in LRRK2, GBA1 and SCNA genes are important risk factors for PD 
(146,147). These genetic variants are relatively common in certain populations but their 
penetrance is on the other hand reduced (147).   
GBA1, which encodes the enzyme β-glucosylceramidase (GCase), is mutated in Gaucher 
disease (GD), the most common lysosomal storage disorder.  GD is an AR, panethnic 
condition with a prevalence of 1:57000, this prevalence is higher for Ashkenazi Jews (1:855) 
among whom the carrier frequency of GBA1 mutations is 1:18 (148,149).  Defective GCase in 
GD leads to accumulation of glucoscylceramide in various organs and highly variable 
manifestations including hepatosplenomegaly, anemia, cytopenias, skeletal abnormalities 
(pain crisis, fractures and osteonecrosis), occasional pulmonary symptoms and varying 
neurological features.  
Classically, three types of GD have been described based on the presence of neurological 
symptoms. The most common is type 1(GD1), long considered to be “non-neuronopathic” (94 
% of cases); type 2 (GD2) is the infantile and fatal form (1.1% of cases) and type 3 (GD3) the 
neuronopathic type (5% of cases). AO for GD2 and GD3 is less than two years, but 
progression of GD3 is slower allowing survival into the third or fourth decade of life (149). 
Untreated patients with GD3 survive to the median age of 11.8 years (150). The features of 
these three forms of GD overlap exist; it is noteworthy that the remaining GCase activity does 
not correlate with phenotype severity (151). In Norrbotten and Västerbotten provinces in 
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Table 5: Summary of known monogenic forms of Parkinson’s disease and risk loci 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Hernandez DG, Reed X, Singleton AB. Genetics in Parkinson disease: Mendelian versus non-Mendelian inheritance. J 
Neurochem. 2016 Oct;139 Suppl 1:59–74. 
Locus Pattern of 
inheritance 
Gene Gene product MIM number 
Park1/Park4 AD SCNA α-synuclein 168601/ 605543 
Park2 AR PARK2 Parkin 602544 
Park5 AD UCHL1  Ubiquitin c terminal hydrolase 613643 
Park6 AR PINK1 Pten-induced putative kinase 1 605909 
Park7 AR PARK7 DJ-1 606324 
Park8 AD LRRK2 Leucine-rich repeat kinase 2 607060 
Park9 AR ATP13A2 Lysosomal type 5 ATPase 606693 
Park11 AD GIGYF2 GRB interacting GYF protein 2 607688 
Park13 AD HTRA2 HTRA serine peptidase 2 610297 
Park14 AR PLA2G6  Phospholipase A2 612953 
Park15 AR FBXO7  F-box only protein 7 260300 
Park17 AD VPS35  Vacuolar protein sorting 35 614203 
Park18 AD EIF4G1  Eukaryotic translation initiation factor 4 gamma 1 614251 
Park19 AD DNAJC16  DNAJ/HSP40 homolog subfamily C member 6 615528 
--- Risk locus SCNA α-synuclein 168601/ 605543 
--- Risk locus LRRK2 Leucine-rich repeat kinase 2 607060 
--- Risk locus GBA Glucocerebrocidase 168600 
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northern Sweden, the prevalence of GD3 (1:17500 inhabitants) is unusually high due to a 
founder effect. This cluster, referred to as the Norrbottnian type of GD3, is associated with 
homozygoty for L444P in GBA1 (152–154); its clinical presentation, even within families, is 
considerably heterogeneous and includes ataxia, spasticity, OMA, squint, seizures, varying 
degrees of cognitive impairment and kyphosis (150). In other GD3 cohorts, myoclonic 
epilepsy has been reported (155). Until 1965 splenectomy was performed in all the 
Norrbottnian GD3 patients but this practice was abandoned when its detrimental effects on 
progression of neurological symptoms became evident (150,156). Enzyme replacement 
therapy (ERT) and  substrate reduction therapy (SRT) are the current treatment options (157).  
Different attempts to estimate the risk that patients with GD and those heterozygous for GBA1 
run of developing PD have given disparate results (158,159). One such study estimated a 20-
fold increased risk (160). However, for a large number of Ashkenazi Jews this risk was 
estimated to be 4.7% and 1.5%, respectively, at 60 years of age; 9.1% and 7.7% at 80 and 
0.7% and 2.1% non-carriers (161). These values are lower than those arrived at in the UK and 
France, which may reflect differences in genotype and other genetic factors (e.g. LRRK2) not 
tested (162,163).  
Genoytpe-phenotype correlations can be made to some degree in GD and GBA-associated 
parkinsonism. Of the more than 300 GBA1 mutations identified to date, the most common 
mutation worldwide in both Jewish and non-Jewish populations is N370S. N370S has been 
considered a mild mutation but is overrepresented in cases of GD-PD cases, L444P is also 
common in patients with GBA-associated parkinsonism (158,164). Those homozygous for the 
N370S mutation tend to display milder symptoms of GD than those who are compound 
heterozygous. In contrast, homozygosity for L444P is usually associated with a more severe 
phenotype, either GD2 or GD3; in one cohort L444P accounted for 42% of GD3 cases but the 
mutation also occurs in GD1 (149,157). In addition to their well-documented association with 
PD, GBA1 mutations are also risk factors for DLB and MSA (165,166). 
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10. AIMS 
The general aim of this thesis was to characterize a group of familial hyperkinetic diseases 
and to try to establish genotype-phenotype correlations when possible. The specific aims 
were: 
- To describe the natural history of IPD with 8-OPRIs and to determine the impact of 
polymorphism in codon 129.  
- To elucidate the genotype of a novel AR ataxia syndrome with features overlapping 
those of AOA1 and AOA2.  Secondly, to assess potential genotype-phenotype 
correlations for AOA4 and MCSZ.  
- To perform a comprehensive characterize in detail two Swedish SCA4 families, 
broadening the neuropathological study and elucidating the underlying mutation. 
Secondly, to compare Biemond’s ataxia with SCA4. 
- To characterize the phenotype and genotype of the F13 family with  brain 
calcifications, to describe the natural history of disease in this family and in a patient 
harboring the R467X mutation in SLC20A2 and to screen for biomarkers in 
cerebrospinal fluid (CSF) for these two different forms of primary familial brain 
calcifications (PFBC).  
- To study the course of disease over a three-year period in two Swedish GD cohorts: 13 
patients with GD1 and 12 Norrbottnian patients with GD3.  
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11. MATERIALS AND METHODS 
11.1 Patients 
The patients included in these studies were referred either to the Department of Neurology or 
the Department of Human Genetics at the Karolinska University Hospital. For Paper I data 
was collected from medical records and previous publications.  For the other papers, the 
patients were examined in a manner appropriate to their clinical presentation.  All the studies 
included here were approved by the Regional Ethics Committee in Stockholm and oral and 
written consent were obtained from the patients or next-a-kin.  
11.2 Methods 
The approaches and rating scales employed in each investigation are described in great detail 
in Tables 6 and 7. The Total calcification score (TCS) and coregistration were used to assess 
the size and potential progression of brain calcifications. The Modified Severity Scoring Tool 
(mSST) was utilized to evaluate patients with Gaucher disease type 3.  
 
11.2.1 Total Calcification Score (TCS) 
The TCS involves rapid and user-friendly visual rating of the following brain structures: 
caudate nucleus, lentiform nucleus, thalamus, white matter, cortex, cerebellar nuclei, vermis, 
midbrain, pons and medulla. Each of these structures is assigned a score ranging from 0-5, so 
that the maximal TCS is 80. Two radiologists must agree on the scoring (131). 
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Table 6: Methods employed in the present thesis 
Method Paper(s) 
Polymerase chain reaction (PCR) and Sanger sequencing I, II, IV and VI 
Whole-exome sequencing (WES) II 
Multipoint linkage analysis III 
CSF analysis III, V and VI 
Western blotting for PNKP, GAD65 and calretinin protein  II and III 
Brain MRI II, III, IV, V and VI 
Peripheral nerve magnetisation transfer ratio  and peripheral nerve diffusion tensor MRI  III 
[11C]Flumazenil-PET and [18F]FluoroDeoxyGlucose(FDG)-PET III 
Neuropathological studies and immunohistochemistry (IHC) III 
Brain CT scans IV, V and VI 
Dual-energy computed scans (DECT)  V 
40-item University of Pennsylvania Smell Identification Test (UPSIT) VII 
(123)I-N--Fluoropropyl-2b-carbomethoxy-3b-(4-iodophenyl) nortropane ((123)I-FP-CIT)-DaTSCAN 
(123I-FP-CIT (DaTSCAN®) 
VII 
Electroneurography (ENeG), electromyography (EMG), II, III, VI and VII 
Quantitative sensory test (QST), variability of RR-interval, skin sudomotor response (SSR), ambulatory 
polysomnography with Embletta and  hearing tests 
III 
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Table 7: Rating scales and cognitive tests applied in the studies on which this thesis is based. 
Rating scale/tool 
 
Paper(s) 
Hospital Anxiety and Depression Scale (HADS) III, V and VII 
Composite Autonomic Symptom Score (COMPASS) III 
Tremor rating scale (TRS) V and VI 
Unified Parkinson's Disease Rating Scale (UPDRS)  V, VI and VII 
Scale for the Assessment and Rating of Ataxia (SARA) and Inventory of non-ataxia Symptoms (INAS) II, III, IV, V and VI 
Unified Huntington’s disease rating scale (UHDRS) V and VI 
modified Severity Scoring Tool (mSST) VII 
Brief cognitive status: Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE)  II, III, V, VI and VII 
General intellectual ability (IQ): Ravens Progressive Matrices V 
Evaluation of verbal episodic memory: Rey Auditory Verbal Learning Test RAVLT (RAVLT) and Buschke’s 
Free and Cued Selective Reminding Test (BFCSRT) 
V and VI 
Visuospatial episodic memory: Rey Osterrieth Complex Figure Test (ROCFT) V and VI 
Assessment of working memory: digit span of the Wechsler Adult Intelligence Scale (WAIS-III) or WAIS-IV V and VI 
Assessment of spatial/visual construction: ROCFT, Copy and Block Design/WAIS V and VI 
Assessment of working memory: digit span of the Wechsler Adult Intelligence Scale (WAIS-III) or WAIS-IV V and VI 
Assessment of spatial/visual construction: ROCFT, Copy and Block Design/WAIS V and VI 
Verbal concept formation: Similarities in WAIS-III V and VI 
Word fluency: Controlled Oral Word Association Test (FAS/COWAT) V and VI 
Picture Naming: Boston Naming Test (BNT) V and VI 
Information processing speed: Symbol Digit Modalities Test (SDMT) V and VI 
Executive function: Trail Making Test, B (TMT) V and VI 
Motor speed: Finger-tapping test (FT), dominant and non-dominant hand V and VI 
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11.2.2 Coregistration 
In Paper V coregistration with fusion software was used to optimize comparisons between 
CT scans. With this approach, 3D regions of interest (ROI) in the reference first CT scan 
propagate semiautomatically to the follow-up CT scan. The relative and absolute changes in 
Hounsfield units (HU) were then determined (Integrated Registration, GE AW server 2) and 
the average of several ROIs used in order to minimize errors. The number of 3D-ROIs 
utilized varied from 1 to 4 depending on the size of the calcifications. A modified version of 
this coregistration approach was used in Paper VI since an automated optimal 3D match 
between CT sections was not possible to obtain in this case.  Here, two experienced 
neuroradiologists matched the images as exactly as they could and chose multiple 2D ROIs 
instead. As with the original method, the HU in these ROIs were determined and the average 
of these measurements used to calculate the differences. Increases of more than 10 HU were 
considered significant in both cases. 
11.2.3 The Modified Severity Scoring Tool (mSST) 
One of the scales employed to assess patients with GD3 is the modified Severity Scoring Tool 
(mSST) which includes 12 domains: gaze palsy, ophthalmology, epilepsy, age at the time of 
first seizure, cognitive ability, ataxia of gait, cerebellar tremor, pyramidal, extrapyramidal, 
swallowing difficulties/oral bulbar function, speech, and spinal alignement. The maximal 
score is 36 points (167). 
 
11.2.4 Statistical analysis 
Descriptive tests (means ± SEM) were used as well as two-tailed paired t tests were used to 
explore the statistical significance of the difference between two values.  A value of p < 0.05 
was considered significant. The statistical analysis in Paper I was performed with the SPSS 
package 20 and included graphs, survival curves, linear regression, ANOVA tests and 
Person’s correlation. Most of the cognitive data in Papers V and VI are presented as z scores 
and compared to reference values with a z score ≤ -1.5 SD indicating a significant deficit 
(168,169).  
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12. RESULTS AND DISCUSSION  
Two hyperkinetic syndromes in a family afflicted by IPD with 8-OPRI and a single case of 
AOA4 were characterized (170,171). 
12.1 The impact of polymorphism in codon 129 in IPD with 8-OPRI (Paper I) 
The four families with 8-OPRI included a total of 30 patients, 7 of whom were members of 
the Swedish family. The Swedish family demonstrated significantly longer survival (mean = 
15.1 years, SD = 4.3 years) than the other three. An inverse correlation (r = -0.642) between 
early AO (mean = 29.7, SD = 5.4) and long survival was observed, a pattern similar to that 
described  for a large English family with 6-OPRI (172). In general, survival was longer than 
for cases of sCJD (median = 5 months), iCJD (median = 13 months), vCJD (median = 13 
months), fCJD (median = 4 months) or FFI (median = 12 months) (173).  
Polymorphism in codon 129 exerted a complex influence on IPD with 8-OPRI. For instance, 
patients harboring the 129M in the mutated allele had earlier AO, longer survival and earlier 
age of death than those carrying 129V. Furthermore, those homozygous for 129M had earlier 
AO than those homozygous for 129V and women had significantly earlier AO and earlier age 
of death than males (30.7 versus 40.4 years). Regression models demonstrated that as much as 
50% of the variability in AO was determined by the combined effects of PRNP polymorphism 
in codon 129 and gender.  
Analysis of the pooled clinical features, neuroimaging and biochemical data available in the 
four 8-OPRI families showed that psychiatric manifestations including personality changes, 
aggressive behavior, manias and perseverations were the most common symptoms at disease 
onset. Dementia was a universal feature while ataxia (50%) and parkinsonism (43%) were the 
most common motor features. Chorea occurred in only 13% of cases, thus, referring to IPD 
with 8-OPRI as HDL1 may be misleading. The different phenotypic features emphasized by 
different groups illustrate ascertainment bias.  
The course of disease in one of the patients (III:3) of the Swedish 8-OPRI family is described 
in Paper I. We found no evidence of learning disabilities during childhood or antisocial traits 
such as those reported for family M-E as well as in association with two other PRNP 
mutations (88,90,174). Anticipation has been suggested in IPD with 8-OPRI but the small 
sample size did not allow a definitive conclusion (88,170). Anticipation was also proposed to 
occur in connection with the E200K mutation (175), but this was questioned in a larger study 
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(176). After Paper I was published another case of 8-OPRI with a GSS phenotype was 
reported in the US (177).  
Variable cerebral and/or cerebellar atrophy was evident in the four 8-OPRI families; in one 
case, hyperintensities of the basal ganglia were present. Brain atrophy, particularly in the 
temporal lobes, was detected in patient III:3 who was shown by HMPAO-SPECT to have 
reduced blood flow in parietotemporal areas. Similar impaired flow in a female patient from 
the Dutch 8-OPRI family has been reported (87). Among the 13 of 30 patients for whom EEG 
data were available 9 exhibited diverse abnormalities and 4 periodic sharp waves complexes 
(PSWC). None of these four publications report on elevated levels of 14-3-3 in the CSF 
(39,87,88,178), which along with PSWC are part of the diagnostic criteria for possible sCJD 
(179).  
Genotype-phenotype correlations can be established for some PRNP mutations. For instance 
E200K, the most common PRNP mutation, is typically associated with fCJD while P102L is 
associated with GSS. Other mutations have also been associated with these phenotypes, but 
only D178N–129M is associated with FFI (54,173). Phenotypes associated with IPD with 
additional OPRI are highly variable and overlapping. The findings documented in Paper I are 
in line with these observations. The structure of the OPRI expansion in the four 8-OPRI 
families is unchanged at the amino acid level (88,170). Thus, PRNP polymorphisms other 
than codon 129 and disease modifiers in other genes may explain the striking differences in 
survival. Transmission experiments could not be performed because the brain tissue of the 
most recent case (III:3) was fixed in formalin. in the English 6-OPRI family Mead and 
colleagues demonstrated a pattern of transmission similar to that for sCJD (172). The type of 
underlying prion strain is still unknown in IPD with 8-OPRI.  
This investigation had some limitations. First, PRNP polymorphisms other than those in 
codon 129 were not assessed. The small sample size precluded comparisons between 
homozygous and heterozygous in codon 129 as well as proper assessment of anticipation. 
Neither the type of underlying prion strain nor prion-oriented neuropathology was performed 
due to lack of access to brain tissue. Proper transmission in a transgenic mouse model remains 
to be performed for IPD with 8-OPRI, but the brain and spinal cord of patient III:3 were 
maintained in formalin which attenuates transmission (180). Finally, biochemical 
abnormalities (e.g. levels of CSF-14-3-3) need to be explored in order to identify and validate 
biomarkers for different types of prion disease.  
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12.2 Novel features of AOA4 
The starting point for the present study was a clinical investigation on a 30 year-old Swedish 
woman born to non-consanguineous parents and afflicted with a complex hyperkinetic 
syndrome. Trio whole-exome sequencing (WES) (i.e. patient and both non-symptomatic 
parents) was employed after polyQ SCAs, Friedreichs ataxia and AT were ruled out.  
Sequencing and MLPA analysis of the APTX (mutated in AOA1) and SETX (mutated in 
AOA2) genes prior to mass sequencing were also normal. Paper II describes insidious onset 
of dystonia and chorea at age 5, at age 12 the patient demonstrated ataxia and was diagnosed 
with pervasive developmental disorder.  Areflexia first and finger contractures with distal 
muscle wasting, loss of proprioception and vibration as well as bilateral foot drop became 
evident as the disease developed. ENeG and EMG examinations revealed combined 
sensorimotor demyelinating and axonal polyneuropathy. Dystonia and chorea receded 
spontaneously with time. At the age of 24 this patient underwent gastric binding for obesity. 
Since age 25 she can only walk with support and has been in a wheel-chair. Increased saccade 
latency, broken smooth pursuit and nystagmus were evident upon examination, but OMA was 
absent. Hypoalbuminemia, hypercholesterolemia and a mildly elevated AFP were present, so 
treatment with simvastatin and a protein-enriched diet was initiated.  Neuroimaging displayed 
progressive cerebellar, without atrophy in the brain stem. The phenomenology of this case is 
displayed in a video clip attached to the publication (171). 
Paper II describes features not previously associated with AOA4, e.g. chorea and slower 
disease progression. OMA, a universal feature in the Portuguese AOA4 cohort, and variable 
feature in A-T, AOA1-3 and related disorders was absent (Table 4). Both dystonia and 
cognitive impairment are also common features in the Portuguese AOA4 cohort. The time to 
wheelchair in the Swedish patient was longer than in the Portuguese cohort (20 versus 13 
years). Obesity described in 30% of all reported cases of AOA4 may provide a diagnostic 
clue, since this is not commonly seen in other ARCA with oculomotor apraxia. Obesity also 
occurs in connection with Joubert syndrome type 8, but this disease is far more severe and its 
radiological features (”molar tooth sign”) distinctive (181). Subsequent to the submission of 
Paper II, two additional cases of AOA4 in Brazil and Norway have been reported (182,183). 
Ataxia and polyneuropathy were present in those patients, but not dystonia or chorea. In the 
Brazilian patient peripheral neuropathy was predominant,preceding ataxia and cognition was 
normal (182). The Norwegian patient displayed mild cognitive impairment and developed 
severe anasarca as the result of hypoalbuminemia. Her neuroimaging revealed widespread 
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atrophy of the brain, cerebellum and brain stem as well as hyperintensities in the middle 
cerebellar peduncles (183). In AT, ATM activity is correlated to phenotype severity (97). 
Whether this also explains the degree of disease severity in cases of AOA4 and MCSZ 
remains to be determined.  
ENeG and EMG examinations revealed demonstrated sensorimotor demyelinating and axonal 
neuropathy in three cases of AOA4 (171,183,184) and sensorimotor demyelinating 
neuropathy and axonal neuropathy, respectively, in two other cases (182,184). All of the 
Portuguese patients had peripheral neuropathy but of which type was not reported (64). One 
of the authors informed us that they had detected axonal neuropathy in 6 AOA4 patients 
(personal communication from Dr Barbot). A summary of the PNKP mutations and associated 
phenotypes are summarized in Table 8. The biochemical abnormalities associated with AOA4 
include those observed for AOA1 and AO2, i.e. hypocholesterolemia, hypoalbuminemia and 
elevated AFP. These abnormalities have yet to be reported in MCSZ.  
Two new compound heterozygous variants in the kinase domain of the PNKP gene, 
c.1196T>C (p.Leu399Pro) and c.1385G>C (p.Arg462Pro), were identified by WES. These 
variants, confirmed by Sanger sequencing and predicted to be pathogenic by in silico analysis. 
The level of PNKP protein in the lymphocytes of this patient was low (Paper II). 
Shen and colleagues have demonstrated not only reduced levels of PNKP, but also impaired 
DNA repairing in cells isolated from MCSZ patients (104). This impairment has also been 
demonstrated by chemical induction of apoptosis with chemicals in cell cultures derived from 
a Brazilian AOA4 patient (182).  
To date, 29 cases featuring MCSZ and AOA4 with 14 different PNKP mutations have been 
described, allowing a certain amount of genotype-phenotype correlation. For instance all of 
the mutations associated with AOA4 are located in the kinase domain of PNKP. Only two 
cases carrying the same homozygous mutation (c.1250_1266dup) in the kinase region has 
been described, in one case it was associated with MCSZ and in a second with combined 
features of MCSZ and AOA4 (104,184). The remaining mutations associated with MCSZ are 
located in the forkhead and phosphatase domains of the PNKP gene (171), suggesting that 
phosphatase may be more important than the kinase activity during embryogenesis.  
As for many other neurological disorders, PNKP mutations are associated with a broad 
spectrum of phenotypes. Only two patients harboring PNKP mutations in association with  
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Table 8: PNKP mutations are associated with non-progressive microcephaly, early-onset of disease, intractable seizures and developmental delay (MCSZ) and 
the progressive ataxia with oculomotor apraxia type 4 (AOA4).  
 
An intermediate phenotype combining features of MCSZ and AOA4 has been described by Poulton et al (2).aThe severe radiological abnormalities in cases of MCSZ include brain and cerebellar atrophy, as well as a 
simplified gyral pattern, thinning of the corpus callosum, enlargement of the ventricles and a reduction of withe matter. All patients with AOA4 patients display cerebellar atrophy and other abnormalities are found. 
bEnlarged ventricles (in one of the siblings), c Hyperintensities in the medium cerebellar peduncles. * Nakashima reported a child with concomitant hearing loss due to PCDH15 mutations. AFP: alpha-fetoprotein; ** P. 
Nair reported a MCSZ patient with short stature and dysmorphism. BA: brain atrophy, BSA: Brain stem atrophy, CA: cerebellar atrophy, CC: corpus callosum, Hyperact: Hyperactivity, Intel. disab. Intellectual 
disability, Microceph: microcephaly, OMA: oculomotor apraxia, PNP: peripheral neuropathy. NA: not assessed. N: no, Y: yes.  
References: 1. Shen J, Gilmore EC, Marshall CA et al. Mutations in PNKP cause microcephaly, seizures and defects in DNA repair. Nat Genet. 2010;42(3):245–9. 2. Poulton C, Oegema R, Heijsman D et al. 
Progressive cerebellar atrophy and polyneuropathy: expanding the spectrum of PNKP mutations. Neurogenetics. 2013;14(1):43–51.  3. Nakashima M, Takano K, Osaka H, et al. Causative novel PNKP mutations and 
concomitant PCDH15 mutations in a patient with microcephaly with early-onset seizures and developmental delay syndrome and hearing loss. J Hum Genet. 2014 Aug;59(8):471–4. 4. Nair P, Hamzeh AR, Mohamed 
M, Saif F, Tawfiq N, El Halik M, et al. Microcephalic primordial dwarfism in an Emirati patient with PNKP mutation. Am J Med Genet A. 2016 Aug;170(8):2127–32. 5. Bras J, Alonso I, Barbot C et al. Mutations in 
PNKP cause recessive ataxia with oculomotor apraxia type 4. Am J Hum Genet. 2015;96(3):474–9.  6. Pedroso JL, Rocha CRR, Macedo-Souza et al. Mutation in PNKP presenting initially as axonal Charcot-Marie-
Tooth disease. Neurol Genet. 2015 Dec;1(4):e30. 7. Paucar M, Malmgren H, Taylor M et al. Expanding the ataxia with oculomotor apraxia type 4 phenotype. Neurol Genet. 2016 Feb;2(1):e49. 8. Tzoulis C, 
Sztromwasser P, Johansson S et al. PNKP Mutations Identified by Whole-Exome Sequencing in a Norwegian Patient with Sporadic Ataxia and Edema. Cerebellum Lond Engl. 2017 Feb;16(1):272–5.
Study author 
(reference) 
 
 
Nr of 
cases 
Microceph Dev. del. or 
intel. disab. 
 
Behav. 
abn. 
Seizures PNP Ataxia Dystonia Chorea OMA Neuroimaging Obesity S-AFP S-Albumin s-Cholesterol Western 
blotting 
for 
PNKP 
Shen et al  
(1)  
11 Y Y 
(11/11) 
Hyperact. Y  
(11/11) 
N N N N N Widespread 
abnormalitiesa 
BA, CA 
N N.A. N.A. N.A. Reduced 
levels 
Poulton et al  
(2) 
2 Y 
(2/2) 
Y 
(2/2) 
Hyperact. Y  
(2/2) 
Y 
(2/2) 
Y 
(2/2) 
N N N BA (2/2) 
CA (2/2)b 
N N.A. N.A. N.A. N.A. 
Nakashima et al  
(3)* 
1 Y Y N Y N N N N N Widespread 
abnormalitiesa 
CA 
N N.A. N.A. N.A. N.A. 
Nair et al  
(4)** 
1  Y Y N Y N.A. N N N N BA 
Agenesis of CC 
 
N N.A. N.A. N.A. N.A. 
Bras et al  
(5) 
11 N Y 
(8/11) 
N N Y 
(11/11) 
Y 
(11/11) 
 
Y 
(8/11) 
N Y 
(11/11) 
CA (11/11) 
BSA (3/11) 
Y 
(4/11) 
Elevated 
(5/11) 
Low  
(6/9) 
Elevated  
(5/9) 
N.A. 
Pedroso et al  
(6) 
1 N 
 
N N N Y Y N N N CA N N.A. N.A. N.A. N.A. 
Paucar et al 
 (7) 
1 N Y N N Y Y Y Y N CA Y Mildly 
elevated 
Low Elevated Reduced 
levels 
Tzoulis et al  
(8) 
1 N Y N N Y Y N N Y BA, CA and BSAb,c N Normal Low Elevated NA 
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ataxia and microcephaly have been described (184). The role of gene modifiers in PNKP 
mutations has not yet been assessed.   
Altogether, the findings documented in Paper II strengthen the association between PNKP 
mutations and AOA4. The reduced level of PNKP protein in the lymphocytes of the Swedish 
patient supports pathogenicity of these PNKP variants. However the exact mechanism(s) 
underlying this disease is still unknown. Shen and colleagues have shown that apoptosis 
occurs in both neuronal precursors and neurons when PNKP is knockdown in vitro (104). 
PNKP is crucial for early embryogenesis, since transgenic mice harboring the most common 
mutation associated with MCSZ (T424Gfs) die early in utero. A  hypomorphic mouse model 
of microcephaly exhibits increased apoptosis in the brain (185).    
Single strand break repair (SSBR)/base excision repair (BER) is one of a number of pathways 
for DNA repair (186,187). There is a remarkable selectivity for neurological phenotypes in 
genetic defects of this pathway (PNKP, APTX and TDP1). However, the matter is complex, 
since knockout mice for APTX (mutated in AOA1) and TDP1 (mutated in SCAN1) lack 
evident phenotypes (185,188). In addition, no evidence of microcephaly in cases of AOA1 
and SCAN1 has been reported to date. Microcephaly does occur in connection with other 
severe diseases (e.g. Nijmegen breakage syndrome, RAD50 deficiency and RNF168 
deficiency) associated with genetic defects in DNA repair pathways other than SSBR 
(187,189).  
One limitation to this study is that apoptosis in lymphocytes challenged with UV and/or 
chemicals was not evaluated which was done for other PNKP mutations (104,182,184). It is 
unknown whether AOA4 and the other ataxias associated with genetic damage to DNA repair 
involved inhanced neuronal apoptosis during embryogenesis and/or later in life.  
12.3 The broad spectrum of symptoms in SCA4 (Paper III)  
16 members of the first SCA4 family (Figure 1) and 10 of the second one (Figure 2) displayed 
symptoms. Both families lack the SCA31 mutation. AO was 46.5 years (range 20-60, SD = 
10.5) and disease duration was 31.8 years (range 18-55, SD = 11.3) years. Anticipation is 
again suggested at least in the first family but limited sample size in the previous generations 
precluded a definitive conclusion.  
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Figure 1: Pedigree of the first Swedish SCA4. Anticipation is suggested in one of the   
branches of this family. Dysautonomia was a frequent feature in this family. 
 
Varying degrees of dysautonomia were found in all the subjects examined and documented in 
the other patients. These features included orthostatism, obstipation, abnormal sweating, 
weight loss, central sleep apnea, incontinence, and erectile dysfunction among others.  In two 
cases dysautonomia preceded ataxia. In contrast to previous reports we found that dysarthria 
(n = 14) and dysphagia (n = 10) were common. In addition to abnormal cerebellar eye 
movements, there were abnormalities associated with brainstem dysfunction (e.g., slow 
saccades and/or varying degrees of ophtalmoplegia), as well as movement disorders other 
than ataxia like dystonia, laryngospasm and chorea. Weakness, myokymias and Babinski’s 
sign were evident in some patients and presbyacusis present in four patients from both 
families. Cognitive decline was documented in two patients only, following a stroke and 
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during the final year of life, respectively. In the latter case neuropathological features 
compatible with Alzheimer’s disease were present.  
 
Figure 2: Pedigree of the second Swedish SCA4 family. Dystonia afflicted some of the 
patients in this family. 
 
All of the patients examined with neurography displayed an axonal sensorimotor neuropathy, 
and impairment of small fibers was also detected. Peripheral neuropathy is common among 
cases of SCA in general (190), but universal in SCA4 where dysautonomia is also more 
common than for other SCAs. These phenotypic features are compared to previous reports in 
Table 9. 
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Table 9: Comparison of the two Swedish SCA4 families to the two families published previously  
 
 
 
* Atrophy in the brainstem and spinal cord was evident in all patients examined. Fractional anisotropy was reduced in the sciatic nerve of three 
Swedish SCA4 patients. C.A. Cerebellar atrophy; N.A. Not assessed; N: no; Y: yes.  
References: 1. Flanigan, K., Gardner, K., Alderson, K., Galster, B., Otterud, B., Leppert, M.F., Kaplan, C., Ptácek, L.J., 1996. Autosomal 
dominant spinocerebellar ataxia with sensory axonal neuropathy (SCA4): clinical description and genetic localization to chromosome 16q22.1. 
Am. J. Hum. Genet. 59, 392–399. 2. Hellenbroich, Y., Bubel, S., Pawlack, H., Opitz, S., Vieregge, P., Schwinger, E., Zühlke, C., 2003. 
Refinement of the spinocerebellar ataxia type 4 locus in a large German family and exclusion of CAG repeat expansions in this region. J. Neurol. 
250, 668–671. doi:10.1007/s00415-003-1052-x. 3. Paucar, M. et al. Broad clinical spectrum and widespread neurodegeneration associated with 
spinocerebellar ataxia type 4. Manuscript. 
Study Age of  
onset  
(mean, years) 
Anticipation Ataxia Peripheral 
neuropathy 
Dysautonomia Eye movement 
abnormalities 
Other  
movement  
disorders 
than ataxia 
Neuroimaging 
Flanigan et al (1) 38.3 Suggested Y Y N Y N N.A. 
Hellenbroich (2) 39.3 Suggested Y Y N Y N C.A. 
Paucar et al 
(manuscript) 
46.5 Suggested Y Y Y Y Y CA among 
others* 
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Neuroimaging revealed variable atrophy in the vermis, pons, medulla, substantia nigra and 
spinal cord.  Fractional anisotropy (FA) in the sciatic nerve was low in patients previously 
found to have periphery neuropathy. 18F-FDG-PET showed a global reduction in brain 
metabolism. Reduced binding in the cerebellum, insula, thalamus and in several cortical 
regions (frontal, parietal, temporal, limbic and occipital) was also observed by 11C-
Flumazenil-PET, indicating loss of GABA-ergic neurons. Setting the ROIs manually did not 
change this reduction in the vermis but made it more apparent in the hypothalamus. The 
significance of this reduction is unclear, but may be related to the dysautonomia in the 
examined patients.    
Assessment of neuropathology in the index case of the first family and case III:2 from the 
second revealed mild atrophy of the vermis and mild-to-moderate loss of Purkinje cells (PC) 
was found in the former, where the number of calretinin-positive cells in the granular layer 
was also reduced. Expected gliosis was evident in the right external capsule and corona 
radiata following a stroke at age 76. In the second case, a mild reduction in cortical thickness, 
widening of the frontal sulci, presence of diffuse neuritic plaques and neurofibrillary tangles 
in the entorhinal cortex and, to a lesser degree, in the hippocampus were evident. In contrast 
to the first case, the loss of PC was moderate to severe and proliferation of Bergmann glia was 
also detected. Both cases demonstrated loss of neurons in the olive nucleus, severe loss of 
motor neurons in the anterior horn, and degeneration of the posterior columns. 
Immunohistochemistry (IHC) analysis of the first case revealed intranuclear inclusions, 
staining for p62 and ubiquitin in the remaining motor neurons of the anterior horn as well as 
accumulation of cells in the vicinity of the central spinal canal. No obvious neuronal loss was 
noticed in the dorsal root ganglia (DRG), but a scarcity of fibers in the ventral and dorsal 
roots was evident. Three cases displayed moderate-to-severe loss of myelinated small and 
thick fibers in the right suralis nerve, with Wallerian degeneration. In summary, these 
abnormalities are far more far-reaching than the neuronal loss in the cerebellum and brainstem 
reported for a German SCA4 patient (117). The only similarities with Biemond’s ataxia were 
degeneration of the posterior columns, mild loss of PC and demyelinization of cerebellar fiber 
tracts (115). In contrast to Biemond’s findings and the German SCA4 case, we found no 
evidence of damage to the trigeminus nuclei. The CSF of two members of the first SCA4 
family was analysed and the level of tau was found to be elevated and beta-amyloid reduced 
in the index case. However, there was no neuropathological evidence of Alzheimer’s disease, 
with normal levels of CSF-NfL in both cases, despite widespread neurodegeneration. In both 
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cases as well, the level of 5-hydroxyindoleacetic acid (5-HIAA) was normal but that of 
homovanillic acid (HVA) elevated, giving a high ratio HVA/5-HIAA that may reflect 
impaired turnover of serotonin.  The level of 4-hydroxy-3-methoxyphenyl glycol (HMPG) in 
the CSF was reduced. The protein levels of GAD65 and calretinin were reduced in the 
temporal cortex and cerebellum respectively in two SCA4 patients. 
Multipoint analysis confirmed linkage to chromosome16q22.1 with a maximum LOD score of 
3.7 being located in a 3.69 cM (25 Mb) region between D16S3086 and D16S512.The second 
family shared the same haplotype markers. However, sequencing of this candidate region did 
not yield clear variants that segregated with disease in either family.  
Although, this description expands the phenotypic characterization of SCA4, the underlying 
mutation remains elusive. Linkage to other chromosome regions than chromosome 16 was not 
analysed which represents a limitation of this work. With respect to neuropathology, 
assessment of the GABA neurotransmitter system and correlation to observed PET 
abnormalities is required.  
12.4 Biemond’s ataxia appears not to be SCA4 
Two of the four generations of Family S were consanguineous and the patients were affected 
by sensory and cerebellar ataxia (Figure 3). In contrast to SCA4, the debut of symptoms was 
subacute in two of these patients who also suffered starvation during World War II. 
Moreover, the symptoms of a third patient were exacerbated by starvation. Other features 
uncommon or absent in SCA4 were present in this family were deafness (1), optic atrophy (2, 
one whom became blind) and chorea (2). In addition three patients did not progress and one 
recovered spontaneously. Aggressive progression leading to death after 6 and 7 years 
occurred in the remaining two patients, one of whom was examined post mortem. Biemond 
found degeneration of the posterior columns, trigeminus nucleus, notorious demyelination and 
mild loss of Purkinje cells, but there was no evidence of cerebellar atrophy. Lack of 
progression and recovery occurred in those exposed to starvation. Taken together, these 
features argue strongly against SCA4. Biemond himself mentioned nutritional deprivation as 
a trigger of disease but wrote about an “endogenous predisposition” (115).  The pedigree of 
family S appears to be pseudodominant, with some patients likely to have been affected by 
Strachan’s syndrome and others to have suffered from an autosomal recessive disease. The 
course of disease in the latter is compatible with either a disorder in peroxisome biogenesis or 
a mitochondrial disorder but the exact etiology of Biemond’s ataxia remains obscure. After 
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the claims made by Flanigan and colleagues, two other contentious descriptions of Biemond’s 
ataxia have been published (191,192).  
                                                   
 
Figure 3: Pedigree of family S as with the same numbers used by Biemond. Notice the 
consanguinity in two generations. Symptom onset was subacute in patients 2, 3 and 4, who 
also suffered from starvation during World War II. Symptoms were exacerbated during 
starvation in patient 2. On the other hand, insidious onset but aggressive course of disease was 
described in patients 1 and 6, with disease duration of 6 and 7 years respectively. In addition 
patients 3, 4 and 5 did not progress and one recovered partially spontaneously (Patient 2).  
Reference: Biemond, A., 1954. Radiculo-posterior cord form of spinocerebellar 
degeneration. Rev. Neurol. (Paris) 91, 3–21. 
 
12.5 Mutations in PDGFB cause brain calcifications (Paper IV)  
The study described in Paper IV started as a clinical investigation of a family (referred to 
hereafter as F13) with autosomal dominant brain calcifications, where the father and three of 
his children were affected. This family was included in a multicenter cohort investigated by a 
team lead by Professor Geschwind and Coppola at University of California Los Angeles. In 
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Paper IV a cohort of 6 PFBC families of diverse ethnic backgrounds with a total of 31 
patients was characterized. This cohort was screened for secondary causes of brain 
calcifications, and then for mutations in the SLC20A2 and PDGRFB genes later. This led to 
the discovery that mutations in PDGFB can cause brain calcifications. PDGFB encodes 
platelet-derived growth factor subunit B, the main ligand of PDGRFB.  
The symptoms documented here included movement disorders (14), migraine (13) and 
cognitive deficits or psychiatric symptoms (9); some were asymptomatic (5) despite the 
presence of calcifications. The average AO was 23.9 years. Brain calcifications were located 
in the basal ganglia, thalamus, white matter and cerebellum. WES was first performed on two 
families, and later Sanger sequencing of the entire coding regions of PDGFB in 30 PFBC 
families, as well as 22 sporadic cases. Of the six pathogenic PDGFB variants identified, the 
mutation c.26T>G (L9R) was carried by all the patients and none of the healthy controls in 
family F13 (193). 
Since PDGFB knockout in mice leads to early death, a hypomorphic PDGFB 
ret/ret
 mouse 
model was employed to obtain functional evidence of pathogenicity. This model is well-
known for its severe glomerular and retinal defects, but normal life-span due to pericyte loss 
and increased permeability of the blood-brain barrier (BBB) (194,195). In paper IV 
progressive brain calcifications, in the basal forebrain, thalamus, midbrain and pons 
containing calcium phosphate, were demonstrated in the PDGFB 
ret/ret
 mice. Previous 
investigations have shown that the gene product of the hypomorphic PDGFB 
ret/ret
 model is 
truncated in these animals (194). The PDGFB gene contains 7 exons and its product is a 
dimer. The L9R mutation in the signal peptide (exon 1) of PDGFB is predicted to disrupt its 
function.  Subsequently, Vanlandewijck and colleagues (196) found the protein levels of 
PDGFB were undetectable when expressed in vitro. In addition, this mutated protein failed to 
activate its receptor (PDGFRB). Paper IV suggested a correlation between the degree of 
pericyte loss in the brain and calcifications. However, it was later demonstrated that the 
calcified areas have a more intact BBB than non-calcified areas (196). 
12.6 Progressive symptoms and brain calcifications associated with a mutation in 
PDGFB (Paper V) 
In paper V the F13 family was followed–up and their brain calcifications and signs found to 
be progressive. The clinical features of four patients were documented by video recordings. 
The mean clinical follow-up was 5.5 years and time that elapsed between two successive 
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brain CT scans 4.8 years. All the four patients were diagnosed with migraine with aura and 
displayed mild eye movement abnormalities. The index case (III:1), was diagnosed with 
anomia, cognitive deficits and has since developed posturing and chorea. One of her siblings 
(III:2) has a history of mixed substance abuse and developed chorea despite the absence of 
radiological progression. The youngest sibling (III:3) exhibited chorea, mild postural tremor 
and cognitive deficits. Their father (II:3) has developed mild motor features with impaired 
tandem gait.  
Radiological examination revealed that patient II:3 has calcifications in the lentiform nucleus 
and white matter only. The three patients in generation III have calcifications in these regions 
as well as in the caudate nucleus, thalamus and dentate nucleus (Figure 4). The TCS indicated 
progression in two cases (III:1 and III:3) and the coregistration procedure progression in three 
(II:3, III:1 and III:3).  
Saeed and colleagues demonstrated that the oxysterol 24(S)-hydroxycholesterol (24S-OHC) is 
low in the brain but increased in the circulation of the hypomorphic PDGFB 
ret/ret
 mouse 
model which is compatible with impaired BBB integrity (197). In contrast, oxysterol levels 
were normal in both the plasma and CSF of three patients from generation III.  At the same 
time, the level of CSF-neurofilament light chain (CSF-NfL) was mildly elevated in the patient 
with clear cognitive impairment (III:3). The index case (III:2) had a mildly elevated albumin 
CSF/serum ratio.  
Paper V provides documents clear evidence of clinical and radiological progression for 
PDGFB-associated PFBC. Two modalities of coregistration, with greater sensitivity than 
TCS, detected the progression of calcifications, although the former are more time-consuming 
(Papers V and VI).  Another advantage with coregistration is overcoming the ceiling effect 
of TCS. Calcifications in PFBC have been assumed to be progressive on the basis of 
distribution of TCS at different ages, but only in one genetically confirmed case has 
radiological progression been reported (198).  
12.7 Elevated levels of phosphate in the CSF of a patient with a mutation in SLC20A2 
(Paper VI) 
In Paper VI a Swedish patient with impaired balance, cognition and brain calcifications 
(Figure 5) was found to harbor the c.1399C>T (R467X) mutation in the SLC20A2 gene. The 
same mutation was reported previously in a Japanese male affected by paroxysmal 
kinesigenic dyskinesias (PKD) (199). The radiological penetrance in the Japanese case was 
reduced, but this feature was not possible to evaluate in the Swedish patient who had a 
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medical history of type 1 diabetes (T1DM) with complications. AO was 42, her phenotype 
was assessed and documented by video recordings.   
                                          
 
                                           
 
                           
 
Figure 4: Neuroimaging of the index case (III:1) in family F13 displaying progressive 
calcifications in the cerebellum, thalamus, basal ganglia (lentiform and caudate nuclei) and 
frontal white matter. On the left axial (upper and middle panel) and sagittal sections (lower 
panel) from the first CT scan at age 27 and to the right corresponding scans performed 5 years 
later.  
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Figure 5: Neuroimaging of a patient carrying the R467X mutation in the SLC20A2 gene. This 
patient is afflicted by ataxia and dementia. The axial CT scans (B and D) display progressive 
calcifications. The first CT scan (B) was performed at age 50 and the second (D) three years 
later. Calcifications in the cerebellar dentate nuclei are confluent and merge in the vermis (A 
and B). Symmetric and dense calcifications are also widespread in the thalamus, lentiform and 
caudate nuclei with milder calcifications in the occipital sulci.  
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Ataxia, subcortical dementia, dystonia and supranuclear palsy were the main features of this 
phenotype. This patient also suffered from psychiatric disorders (restlessness, lack of insight 
and delusions). The TCS was high, in line with previous findings in carriers of SLC20A2 gene 
mutations as compared to other forms of PFBC. These calcifications were found to be 
progressive by coregistration, but not TCS.  Her CSF-NfL was elevated 6-fold; in addition her 
CSF-phosphate (CSF-Pi) was also elevated in comparison to seven healthy controls (41% 
higher) and one male patient from the F13 family (III:2).  Elevated CSF-Pi and progressive 
brain calcifications have been demonstrated in knockout and haploinsufficient SLC20A2 +/- 
mice (200–202). Data on CSF analyses is very scarce in PFBC, Manyam and colleagues 
found elevated homocarnosine in 2 patients belonging to a Canadian family that has been 
described in several articles and later found to harbor mutations in both SLC20A2 and THAP1 
(203,204). Hozumi and colleagues analyzed metals in three patients with calcifications but 
these patients lacked a family history of brain calcifications (205). In both cases described in 
Papers V and VI, CSF-NfL was elevated lending support to the notion that PFBC are 
neurodegenerative diseases. There is a discrepancy between the increased BBB permeability 
demonstrated in the hypomorphic PDGFB
ret/ret 
mouse model (195,197) and the CSF findings 
in patients of the F13 family. Whether the permeability of the BBB changes with age and/or 
depend on the underlying mutation type remains to be studied. Paper VI suggests that 
elevated CSF-Pi may be a potential biomarker for PFBC associated with PFBC.  
Both radiological and clinical penetrance has been described in PFBC. The radiological 
penetrance is very high but the clinical penetrance reduced and estimated to be around 60% 
(132,133) which may well be an underestimation since several features are subtle. Only 
detailed evaluation revealed significant cognitive deficits and anomia in two of our patients 
(Paper V). Clinico-anatomical correlations are difficult to establish clearly in PFBC. For 
instance, ataxia was more common among patients with calcifications in the basal ganglia, but 
not in the cerebellum.  
The frequency of symptoms and signs reported in genetically proven PFBC cohorts and in 
one systemic review varies widely; from 14-61% for movement disorders, 15-59% for 
cognitive impairment, 15-76% for psychiatric symptoms and 20-36% for migraine/other 
headaches (132,133). In that systemic review, mean AO for SLC20A2 and PDGFRB mutation 
carriers was 31.7 and 16.3, respectively. However, incomplete data is highlighted as a limiting 
factor in the analysis (133).  
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Although the significant overlap in clinical presentation makes diagnosis of PFBC 
challenging, certain conclusions can be drawn.  First, calcifications associated with SLC20A2 
mutations are more severe and widespread than those for other PFBC forms. Such 
calcifications are detected in the cortex and vermis of most carriers of SLC20A2 mutations. 
Calcifications are milder in PDGFRB mutation carriers. Migraine is common in PDGFB-and 
PDGFRB-associated PFBC; however this feature did not segregated well in the latter group. 
Patients with XPR1 mutations may be more affected by cognitive decline (131,132,206,207).  
Neuropathology has provided insights into PFBC, but to date only two genetically-proven 
SLC20A2 mutation carriers have been examined in this respect.  Their calcifications affected 
the tunica media of brain arteries and the brain parenchyma, but not the veins (198,204). In 
addition, immunostaining for PiT-2 was reduced and a faint signal on Western blots of this 
protein was evident in the frontal cortex, putamen and cerebellum (198).  
Mutations in SLC20A2, of which more than 50 have been identified to date, are the most 
common cause of PFBC (208), followed by mutations in PDGFB (10 so far), while mutations 
in PGFBRB and XPR1 are very rare (207,209). What do the PFBC genes have in common? 
The products of SLC20A1, XPR1 and PDGFRB genes are involved in phosphate transport and 
homeostasis (140,141,206). Impaired BBB has been demonstrated in PDGFB and PDGFRB 
null and hypomorphic mice (195,210–212). SLC20A2 is expressed ubiquitously, high levels 
of expression are found in the vascular smooth muscle, parathyroid glands, kidney, gut, bone 
and placental pericytes (213–215).  SLC20A2 is also highly expressed in the brain (neurons, 
endothelial cells and astrocytes), particularly in the calcified areas (214). XPR1 is also 
expressed in several tissues, including the brain (216).  Impaired phosphate transport and 
subsequent hyperphosphatemia in the CSF appear to trigger brain calcifications, at least in the 
SLC20A2 knockout mouse model. It has been proposed that calcification begins in the vessels 
of the brain; hyperphosphatemia in the CSF may trigger this process in a similar manner to 
how hyperphospatemia due to chronic kidney failure leads to calcification of peripheral 
vessels (202,217). PDGFRB is tyrosine kinase receptor, expressed widely in the CNS 
(neurons, pericytes, vascular smooth muscle cells and choroid plexus) (141). PDGFB, the 
main ligand of PDGFRB, is a growth factor expressed in neurons and epithelial cells. 
PDGFRB is crucial for embryonic development, cell proliferation, survival, differentiation, 
chemotaxis and migration. PDGFRB knockout mice die soon after birth (218). PDGFRB 
plays also important roles in the development of blood vessel by promoting proliferation, 
migration and recruitment of pericytes as well as in the regulation of phosphate homeostasis 
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by inducing expression of  the phosphate transporter 1 (PiT-1) in vascular smooth muscle 
cells (141). Activation by PDGFB is required for normal proliferation and recruitment of 
pericytes and vascular smooth muscle cells in the brain, lung, heart, kidney, placenta and skin 
(219). The mechanisms of disease in PDGFRB-PDGFB-associated PFBC are still unknown; 
so far the described mutations associated with brain calcifications are predicted to be loss-of-
function. Functional evidence of PDGFRB mutations were first provided in vitro, however a 
hypomorphic PDFGRB 
red eye/red eye
 mouse model displays retinal degeneration but not brain 
calcifications (196,212,220). Interestingly, some mutations in PDGFRB that are predicted to 
be gain-of-function are associated with a progeria disorder called Penttinen syndrome and 
with an overgrowth syndrome called Kosaki syndrome (221,222). Different to the loss-of- 
function mutations, neither Penttinen nor Kosaki syndromes are associated with brain 
calcifications. A summary of the genes associated with PFBC is shown in Figure 6. 
Dysmorphism has only been described only in one Tyrolean family with a SLC20A2 mutation 
(223,224).  
The risk of incidental brain calcifications increases with age, but there are presently no 
validated normative data in this respect for older age groups. The higher the TCS, the more 
likely the patient is symptomatic (131). Recently, a predictive model for PFBC, based on age 
and number of symmetric calcifications, and claimed to have a sensitivity of 100% and 
specificity of 92% (224). Integrating this algorithm with CSF biomarkers might improve 
diagnostic specificity.  
There is still some confusion around the nomenclature of diseases with brain calcifications, in 
part because of the reassignment of loci during recent years. For instance, the family with 
proposed linkage to chromosome 14 (14q13) was shown later to harbor a mutation in the 
SLC20A2 gene which is located on chromosome 8 (139,208). Likewise, another family with 
proposed linkage to chromosome 2q, carried in fact, a mutation in SLC20A2 (223,224). 
IBGC2 and IBGC3 have merged with IBGC1. Such reassignments illustrate the pitfalls and 
limitations of linkage analysis and genetic testing. The underlying genotype in several PFBC 
families remain to be discovered, for instance Nicolas and colleagues described 47 out of 72 
French patients with probable PFBC with unknown mutation (131).  
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Figure 6: Genes associated with primary familial brain calcifications (PFBC). A. Two of 
these genes, SLC20A2 and XPR1, encoded proteins involved in phosphate transport. SLC20A2 
encodes the phosphate transporter 2 (PiT-2). PDGFB and PDGFRB are involved in cell 
proliferation and pericyte recrutiment. PDGFRB also induces transcription of phosphate 
transporter 1 (PiT-1). B. These mutations lead to alterations in the blood-brain-barrier, in the 
PDGFB 
ret/ret
 mouse model, but not the F13 family, and impaired phosphate transport 
respectively. Hyperphosphatemia in the CSF occurs in knockout SLC20A2 mice. Figure from 
V. Tadic et al in Primary familial brain calcification with known gene mutations: a systematic 
review and challenges of phenotypic characterization. JAMA Neurol. 2015 Apr;72(4):460–7. 
Reproduced with permission.  
 
The studies described in Papers IV, V and VI have certain limitations. First, important 
clinical data was missing for some included in the PDGFB cohort. For example, AO was 
available for only 15 out of the 31 patients in the families included. Furthermore, information 
was available on only two of the four patients from family 10, one affected by headaches did 
not undergp a brain CT scan and the possible symptoms of another relative with brain 
calcifications were not reported. Lack of cognitive assessment of the men from the F13 family 
also limits generalizations concerning the L9R PDGFB mutation. The discrepancy between 
the oxysterol findings on the hypomorphic PDGFB
ret/ret  
mice  and the patients from the F13 
family described above remains to be resolved. Finally, generality of CSF-Pi in SLC20A2 
mutations cannot be claimed until tested in other PFBC patients. 
12.8 Neurological features of two Swedish Gaucher disease cohorts (paper VII) 
In Paper VII a wide phenotypic heterogeneity in 2 Swedish GD cohorts is described (225). 
All but one of the patients in the GD3 cohort (n = 12) were homozygous for L444P GBA1 
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mutations, whereas the GD1 cohort (n = 13) was far more diverse. None of the GD1 patients 
carried biallelic L444P mutations; in the GD1 group, the N370S mutation was most common. 
Two patients with PD were identified in the GD1 cohort, but not in the GD3 cohort. 
Asymmetric rigidity, hyposmia and good L-DOPA response was identified in one GD3 
patient who went through 
123
FP-CIT SPECT. This test demonstrated reduced DAT binding in 
the putamen. Furthermore, mild-to-complete hyposmia, a common non-motor sign in PD, was 
present in 5 GD1 and 6 GD3 patients. Absence of clear Parkinsonism cases in the GD3 cohort 
is in contrast with a recent screening in a large PD cohort in Sweden (1625 patients), which 
identified a significant association with the L444P mutation and the E326K variant. The 
association with L444P was particularly strong in patients from the northern regions (a 
frequency of 4.11%) than  in the country as a whole (frequency of 2.20%) (226).  
Some features in the GD3 cohort are noteworthy, e.g. long survival with six of these patients 
living beyond the age of 40. Facial dystonia and blepharospam were documented in four 
patients while the EMG of several muscle groups, including the face, was normal in two. In 
addition to the features typical of Norrbottnian GD3 type (truncal and appendicular ataxia, 
OMA, variable cognitive impairment and kyphosis), six patients exhibited focal epilepsy. 
However, none of the patients in these cohorts had myoclonic epilepsy as otherwise described 
in other GD3 cohorts (155). Anxiety was more common in the GD1 cohort while impaired 
cognition was evident in 4 GD1 patients and 4 GD3 patients.   
All but two of the GD3 patients underwent splenectomy and all but two were treated with 
ERT, the remaining two receiving bone marrow transplantation (BMT). Treatment regimens 
in the GD1 cohort were more variable, ERT was given most commonly alone (4) or in 
combination with SRT (2). SRT alone was administered to one patient, another was treated 
with BMT and 5 patients did not receive any treatment at all in the remaining GD1 cohort. 
Surprisingly, no members of either of these GD groups demonstrated detectable neurological 
progression in the course of 3 years (cognition or movement disorders). Optimization of anti-
epileptic medication may have influenced this outcome. In contrast, the European GD3 cohort 
showed progression over the course of 4 years (167).  
The genotype-phenotype correlations associated with GD-PD are complex; at least a 
correlation with gene dose has been established in cases of parkinsonism associated with 
GBA1 mutations. The GD-PD phenotype (either homozygous or compound heterozygous 
mutations) is characterized by earlier AO and more severe non-motor features (psychiatric 
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symptoms, dysautonomia, RBD and hyposmia) as well as faster motor progression and more 
severe cognitive decline than in the case of carriers of heterozygous GBA1 mutations and 
patients with iPD (158,164). Intriguingly, the E326K and T369M GBA1 variants recur in 
association with PD but not with GD, implying that the mechanisms underlying GD and PD 
differ (227).   
 
The mechanism underlying GBA-associated parkinsonism is unknown, although a 
bidirectional loop connecting GCAse and α-synuclein has been proposed (228–230). 
Deficient GCase was found to induce increased accumulation and toxicity of α-synuclein in 
vitro, then in GD mouse models and later in the brains of PD patients with and without GBA1 
mutations (161,229,231,232). Recent evidence indicates that this toxicity impairs 
simultaneously time trafficking of both GCase and other lysosomal hydrolases (229)). 
However, the majority of GD patients and heterozygous GBA mutation carriers do not 
develop parkinsonism. Investigation of the potential role of gene modifiers and other 
interactions (gene-environment) will help clarify the variable expressivity of GD and GBA-
associated parkinsonism.  
 
Small sample size is once again a limitation here precluding definitive conclusions concerning 
the long-term prevalence of PD in our two GD cohorts. The Norrbottnian GD3 cohort 
represents the vast majority of GD3 patients in Sweden and the GD1 cohort represents 
approximately half of all the GD patients in the country. In addition, the follow-up time seems 
short as compared with a larger study on GD patients from Central Europe (167). The EMG 
of the cases studied ruled out myokymias and myopathies, although the phenomenology 
presented with concomitant blepharospasm is more compatible with facial dystonia. 
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13. CONCLUSIONS 
The following conclusions can be made for this thesis: 
- The Swedish family affected by inherited prion disease (IPD) with 8-OPRI (HDL1) 
displays an unusually long survival. 
- There is an inverse correlation between early AO and long survival in IPD with 8-
OPRI.  
- Polymorphism in codon 129 of PRNP exerts a major impact on AO and survival in 
IPD with 8-OPRI, accounting together with gender, for as much as 50% of variability 
in AO.  
- Diagnostic clues for AOA4 include the presence of obesity and biochemical 
abnormalities like reduced levels of albumin and elevated levels of AFP and 
cholesterol.  
- A description of a Swedish patient with complex hyperkinetic syndrome associated 
with mutations in PNKP gene strengthens AOA4 as a novel entity. Novel features of 
AOA4 identified in the Swedish patient are the presence of chorea and low levels of 
PNKP protein in blood.   
- Spinocerebellar ataxia type 4 (SCA4) in two Swedish families is associated with novel 
features including dysautonomia, dystonia, small fiber polyneuropathy and widespread 
neurodegeneration.   
- Anticipation is also suggested for one Swedish SCA4 family for which the underlying 
mutation in SCA4 remains to be discovered.  
- Mutations in the PDGFB gene account for the second most common form of primary 
familial brain calcifications.  
- Signs and brain calcifications are progressive in a family with the L9R mutation in 
PDGFB. This family does not display the impaired blood-brain-barrier detected in the 
hypomorphic PDGFB ret/ret mouse model.  
- Ataxia, dementia, supranuclear palsy and widespread brain calcifications are 
associated with the R467X mutation in SLC20A2 in a Swedish patient. Similar to the 
animal SLC20A2 knockout mouse models level of phosphate in her CSF was elevated 
- Parkinsonism was present in a Gaucher disease type 1 (GD1) cohort but not in the 
Norrbottnian Gaucher disease type 3 (GD3) cohort. Some of the latter display features 
that may indicate presymptomatic parkinsonism (e.g., hyposmia, abnormal DAT-
scan).  
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- During a three-year period there was no detectable progression in either if of these 
cohorts. The Norrbottnian GD3 cohort displays unusually long survival, as well as 
dystonia.  
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14. FUTURE DIRECTIONS 
Mass sequencing has revolutionized medicine in the last years, allowing what were previously 
challenging, expensive and time-consuming investigations to be performed much more 
readily, as illustrated in some of the articles included here. A remaining challenge is to 
connect the growing number of genes shown to be involved in neurodegeneration with their 
convergent pathways. There is also a compelling need to identify validated biomarkers and at 
last improve current treatments. To our surprise, CSF-14-3-3 which is widely used as a 
diagnostic tool for sCJD has not been evaluated in this respect for IPD with 8-OPRI. 
Evaluation of PRNP polymorphisms other than codon 129, identification of the prion protein 
strain and transmission studies in IPD with 8-OPRI remain to be done. Our own research 
group is presently carrying out a local HDL screening. 
Several questions concerning PNKP mutations remain to be answered. For instance, we do 
not know whether there is a correlation between the level of PNKP enzyme activity and/or 
protein levels and the severity of AOA4 and MCSZ. There is evidence for enhanced neuronal 
apoptosis in MCSZ at least during embryogenesis, but is this also the case for AOA4? The 
neuropathology for AOA4 also remains to be studied and an animal model is needed. Whether 
the ataxia syndromes associated with genetic defects in SSBR converge with regards to 
pathogenesis/disrupted hubs is unknown. It is striking that defects in SSBR do not predispose 
for cancer in the same manner as for diseases with defective DNA damage signaling (double-
stranded break signaling) like A-T and NBS.  
A thorough analysis of chromosome regions other than 16q in SCA4 patients is necessary.  
IHC analysis of the GABA-ergic and other neurotransmitter systems is ongoing in our 
laboratory and possible correlations with the abnormalities observed by PET imaging will be 
evaluated. SCA4 provides a unique model to study ataxia and dysautonomia. Dissection of the 
neuronal networks disrupted in this disease will provide knowledge for dysautonomia that 
may also be relevant to more common conditions like PD and MSA.    
Despite major and rapid advances in genetic discoveries, many questions have arisen in 
connection with PFBC. We still do not know at what age brain calcifications emerge or their 
their long-term rate of progression.  Longitudinal studies will help to determine the rate of 
clinical progression and penetrance. The value of elevated levels of CSF-Pi as a potential 
biomarker requires assessment of large PFBC cohorts.  In addition, the neuropathology of 
PDGFB- and PDGFRB-associated PFBC remains to be analyzed; only two cases harboring 
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SLC20A2 mutations have examined to date. Also unknown is the role of gene modifiers 
and/or other potential compensatory mechanisms underlying the reduced clinical penetrance 
of PFBC. Characterization of the PDGFB 
ret/ret
 mouse model with respect to movement and/or 
behavioral abnormalities will be hard to interpret due since the BBB damage exhibited by this 
model is not detected in patients harboring the L9R PDGFB mutation. The algorithm for 
prediction of PFBC proposed by Grütz requires validation (224) which we will apply to 
evaluate brain calcifications in CT scans performed at our hospital in connection with 
characterization of a local PFBC cohort.  
Finally, the complex association between GBA1 mutations and parkinsonism will require 
assessment of first degree relatives to patients in the Swedish GD cohorts. The role of 
epigenetic factors in GBA-associated parkinsonism have not been assessed in detail yet. Last 
but not least, there is a need for establishing/defining biomarkers for this association.  
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15. POPULÄRVETENSKAPLIG SAMMANSTÄLLNING 
I denna avhandling beskrivs några sällsynta ärftliga neurologiska sjukdomar som 
huvudskaligen påverkar motoriken. I studie I beskrivs en ärftlig prionsjukdom som går med 
ofrivilliga rörelser, personlighetsförändring, varierande förekomst av psykiatriska symtom 
och även demensutveckling. Ofrivilliga rörelser i denna sammanställning inkluderar chorea 
(snabba och slumpmässiga rörelser) och dystoni (ihållande sammandragning av olika 
muskelgrupper).  Ett annat motoriskt fenomen som tas upp i avhandlingen är ataxi. Ataxi är 
en medicinsk term som beskriver nedsatt koordination och obalans vilket oftast uppstår till 
följd av skador i lillhjärnan. Vanligaste orsaken till ärftlig chorea är Huntingtons sjukdom 
också kallad danssjuka. Liknande symtombild förekommer vid andra ärftliga tillstånd som 
kallats för ”Huntingtonliknande sjukdomar” (Huntington’s disease-like, HDL på engelska). 
Det finns flera olika typer av ärftliga prionsjukdomar, en av dem kallas för 
Huntingtonliknande sjukdom 1 (HDL1). Det har beskrivits fyra olika familjer med denna 
sällsynta sjukdom, en av dem var från Sverige. Alla individer i den svenska familjen är 
avlidna. Symtombilden vid HDL1 består av beteendestörningar, ofrivilliga rörelser, ataxi och 
tidig demensutveckling. Data från alla fyra familjer med denna sjukdom samlades och 
analyserades. Dels visas i denna studie att en annan förändring i prionanlaget påverkar HDL1. 
Den svenska familjen hade den längsta överlevanden av alla fyra familjerna. Tidigare ålder 
vid insjuknandet korrelerade med långt förlopp vid HDL1. 
Studie II i avhandlingen berör en komplex och relativt nybeskriven sjukdom vid namn ataxi 
med oculomotorisk apraxi typ 4 (AOA4). Oculomotorisk apraxi betecknar svårigheter att föra 
blicken åt sidorna på uppmaning. Ett fenomen som sticker ut med AOA4 är övervikt hos en 
tredje del av patienter och avvikande laboratorieprover i form av låg proteinnivå men stegrade 
kolesterol- och AFP-värden. AFP står för alfafetoprotein. En svensk patient med fortskridande 
symptombild i form av ataxi, uttalad polyneuropati (påverkan på perifera nerver) och kognitiv 
påverkan beskrivs. Symtomdebut skedde i barndomen, MR-hjärna påvisat i detta fall 
fortskridande atrofi (skrumpning i lillhjärnan). Nya drag för AOA4 i det beskrivna fallet är 
förekomst av chorea under barndomen, långsam sjukdomsutveckling och låga halter i blodet 
av proteinet som är muterat. Beskrivningen stödjer uppfattningen att AOA4 är en ny och 
distinkt sjukdom.  
Spinocerebellär ataxi typ 4 (SCA4) är en sällsynt sjukdom som beskrevs för första gången hos 
en skandinavisk familj i den amerikanska mellanvästern 1996. Genetiska studier visade att 
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SCA4 var kopplad till beskrevs en region på associerad till kromosom 16q22.1. En annan 
SCA4 familj med koppling till samma region på kromosom 16 rapporterades några år senare i 
Tyskland. Symtombilden vid SCA4 består av debut i vuxen ålder, ataxi och polyneuropati.  
SCA4 är en långsamt fortskridande sjukdom. I studie III i denna avhandling beskrivs två 
svenska SCA4 familjer med bredare och mycket varierande symtombild än vid föregående 
beskrivningar.  Hos majoriteten av undersökta patienter påvisades en varierande grad av 
dysautonomi först. Dysautonomi innebär störning i funktioner som inte styrs viljemässigt 
såsom bl.a. reglering av blodtrycket vid lägesändringar, andningsfunktionen i sömnen, och 
tarmfunktionen. Dysautonomi förekommer vid andra SCA former men är inte lika utbredd 
och vanlig som vid SCA4. Andra motorikstörningar än ataxi konstaterades hos några patienter 
i de svenska familjerna såsom dystoni. Varierande grad av atrofi (skrumpning) i lillhjärnan, 
hjärnstammen och ryggmärgen påvisades i alla de testade patienterna. Andra bildavgivande 
metoder visat generell nedsatt ämnesomsättning i lillhjärnan. En utbredd neurodegeneration 
d.v.s. förlust av flera olika typer av nervceller påvisades i två fall, detta drabbade lillhjärnan 
och oväntad nog även ryggmärgen. Kandidatregionen i kromosom 16 blev avläst men ingen 
uppenbar sjukdomsorsakande förändring kunde påvisas. 
Förekomst av förkalkningar i hjärnan kallas vanligen för” Fahr’s disease”. Det finns en rad 
olika orsaker till förkalkningar i hjärnan. En ovanlig form av detta tillstånd utgörs av en grupp 
ärftliga sjukdomar som samlas under namnet primära och familjära hjärnförkalkningar (PFBC 
engelsk förkortning). Symtombilden vid PFBC är mycket varierande. Studie IV handlar om 
upptäckten av mutationer i en tillväxtfaktor för kärl som orsak till förkalkningar i hjärnan hos 
sex obesläktade familjer från olika länder. En av dessa familjer var en svensk familj som 
utretts på neurologmottagningen. Familjen består av fyra patienter med förkalkningar i 
hjärnan, migrän och ofrivilliga rörelser i form av skakningar och chorea. Hos denna och de 
fem andra familjerna upptäcktes förändringar i tillväxtfaktorn som orsak till förkalkningarna. 
En genmanipulerad musmodell för denna sjukdom analyserades. Denna musmodell uppvisar 
fortskridande förkalkningar i hjärnan och en ökad genomsläpplighet i sin blod-hjärnbarriär. I 
studie V gjordes en uppföljning av familjen med förkalkningar i hjärnan. Hos samtliga 
patienter konstaterades antingen tillkomst av mild obalans eller fortskridande ofrivilliga 
rörelser. Förkalkningarna i hjärnan hade också ökat hos 3 av 4 patienter. I studien 
analyserades ryggvätskan från tre patienter i den svenska familjen och jämfördes med 
musmodellen för denna sjukdom. Till skillnad från musmodellen var blod-hjärnbarriär hos 
patienterna normal. I studie VI beskrivs en patient drabbad av ataxi, personlighetsförändring, 
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nedsatt minne och omfattande förkalkningar i hjärnan. Förkalkningarna var fortskridande 
även i detta fall. Utredningen påvisade en mutation i en gen viktig för fosfattransport i 
kroppen.  En genmanipulerad mus används som modell för denna sjukdom och som uppvisar 
stegrad fosfatnivå i ryggvätskan. Liknande avvikelse konstaterades hos patienten. I båda 
studierna (V och VI) tillämpades en analysmetod för att utvärdera om förkalkningarna i 
hjärnan ökat.  
Gaucher sjukdom (GS) är en autosomal recessiv sjukdom som uppstår till följd av mutationer 
i GBA genen och påverkar framför allt blodbilden. GS delas upp i tre olika typer utifrån 
förekomst av neurologiska symtom: GS typ 1 (GS1) är absolut vanligast och traditionellt sett 
inte associerad med neurologiska symtom. GS typ 2 (GS2) är en mycket svår form som 
drabbar barn och GS typ 3 (GS3) som är associerad med neurologiska symtom.  En särskild 
form av GS3 finns i Norrbotten där majoriteten av alla patienter bär på samma sjukdomsanlag 
i dubbeluppsättning.  Mutationer och varianter i enkel eller dubbel uppsättning i GBA genen 
utgör också en betydande riskfaktor för Parkinsons sjukdom och liknande tillstånd.  I studie 
VII undersöktes en grupp patienter med GS1 (n = 13) och en grupp patienter med GS3 (n = 
12). I GS1-gruppen identifierades fall av Parkinsons sjukdom men inga alls i GS3-gruppen. 
Några patienter hade nedsatt luktförmåga vilket kan föregå Parkinsons sjukdom. Sex GS3 
patienter har levt över 40 år vilket är ovanligt. Dystoni dokumenterades som ett nytt 
motorikfenomen i GS3-kohorten. Ingen grupp hade detekterbar neurologisk progression under 
loppet av 3 år.  
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